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 DEVELOPMENT OF A BIOHYBRID LUNG 
Alexa Ann Polk, PhD 
University of Pittsburgh, 2006
 
Therapy for patients suffering from acute respiratory distress syndrome (ARDS) is substantially 
inadequate, resulting in a 40% mortality rate. A biohybrid lung prototype consisting of a rotating 
endothelialized microporous hollow fiber (MHF) bundle was studied as an alternative solution 
for improved patient outcome. It is hypothesized that endothelialized MHFs could present a 
surface mimicking the native vascular lining to reduce thrombotic deposition on underlying 
MHF. Such an approach might thus allow blood oxygenation and CO2 removal for extended 
periods with reduced anticoagulation requirements. Development of the biohybrid lung 
prototype, evaluation of endothelial cell (EC) response to shear stress, influence of 
endothelialization on gas transfer, and impact of bundle rotational speed on gas transfer and 
alterations in EC phenotype were studied.  
MHFs were surface modified to promote EC attachment and proliferation. 
Endothelialized MHF bundles were rotated in the biohybrid lung prototype up to 1500 RPM 
(29.6 dynes/cm2). Blood-surface biocompatibility testing was performed on MHFs and MHF 
bundles in the biohybrid lung prototype, with or without ECs. Partial O2 pressures were recorded 
for blood samples to measure oxygen buildup within the biohybrid lung. Scanning electron 
micrographs (SEMs) of thrombotic deposition were taken. Upregulation of e-selectin and p-
selectin on ECs were assessed for indication of an inflammatory EC phenotype. 
ECs maintained near confluent coverage on MHFs under rotation at the tested speeds, 
and showed minimal p-selectin expression subsequent to rotation. It was observed that even low 
to moderate levels of EC coverage greatly reduced thrombotic deposition on MHFs. Statistically 
significant differences in oxygen accumulation between MHF bundles with or without 
endothelialization in the presence of 95% O2 were not found. Thrombotic deposition on 
endothelialized MHF bundles was less than or equivalent to thrombotic deposition on non-
endothelialized MHF bundles following rotation. Low levels of e-selectin and p-selectin 
expression were observed following 24 hr hyperoxia.  
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These results suggest that endothelialized MHFs may serve to improve blood-surface 
biocompatibility in the presence of hyperoxia. Although further development and testing is 
required, a biohybrid lung employing endothelialized MHFs and a rotating fiber bundle may 
provide an alternative therapy for patients suffering from ARDS.  
 v 
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1.0  INTRODUCTION 
1.1 OXYGENATION IN THE NATURAL LUNGS 
The natural lung has a tidal volume of approximately 500 mL, which is the total volume of gas 
inspired or expired during each respiratory cycle [1]. Of the total gas, a 70 kg man at rest is 
estimated to produce 240 mL/min of carbon dioxide and consume 270 mL/min of oxygen [2]. 
Blood flows through capillaries in the alveoli to make this exchange possible. Oxygen and 
carbon dioxide exchange occurs across a barrier of capillary endothelial cells (ECs) and 
mucopolysaccharide hydrogel film. A membrane of 0.4-2 μm thickness separates air-carrying 
alveoli from the pulmonary capillaries. Deoxygenated blood from the right side of the heart 
passes through this membrane of the lungs. Oxygen then diffuses across the membrane into the 
blood stream. Carbon dioxide is removed from the blood, into the alveoli, for exhalation [1]. The 
natural membrane appears as a porous, open-cell foam. The surface area of this membrane is 
estimated to be between 70 m2 and 90 m2 [1, 3]. 
1.2 ACUTE RESPIRATORY DISTRESS SYNDROME 
Acute Respiratory Distress Syndrome (ARDS) is an inflammatory lung condition that affects 
nearly 150,000 patients per year in the U.S. [4]. Mortality exceeds 40%, while survivors may 
suffer permanent lung damage and memory loss due to oxygen deprivation during lung 
dysfunction [5, 6]. ARDS is not a disease itself, but a syndrome associated with a variety of 
diseases such as pneumonia, shock, sepsis or trauma, resulting from direct physical or toxic 
injury to the lungs. Common modalities of injury include severe chest blows and aspiration. 
ARDS may also result from an indirect bloodborne injury to the lungs, such as sepsis [7, 8]. 
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Characteristics common to ARDS patients include loss of lung compliance, diffuse alveolar 
infiltration and surfactant dysfunction. An increase in surface tension of the lungs results in 
atelectasis, pulmonary edema and ultimately hypoxemia. This state of deteriorated respiratory 
function requires mechanical ventilation. The condition may persist for several days to months 
[9].  
ARDS is generally characterized by three sequential stages. First, the oxidative stage, is 
described by accumulation of excess fluid and protein in the alveolus. Inflammatory cells from 
the alveolar capillaries infiltrate the alveoli of the lung. Alveoli will rupture as a result of fluid 
buildup, and subsequently leak into the surrounding tissue. The loss of functional alveoli and 
continued fluid accumulation in the lungs results in diminished gas exchange. Second, in the 
fibroproliferative stage, proliferation of connective tissue and other structural elements of the 
lung occur. Continuing inflammation causes the lung tissue to fibrose. There is an increased risk 
for pneumonia, sepsis and rupture of the lungs. As ARDS progresses damage to vital organs may 
occur. The third stage, resolution and recovery, involves reorganization of the lung, which can 
lead to different levels of pulmonary recovery. The lungs may recover completely, respiratory 
dysfunction may persist, or death may occur [7, 8].  
1.3 MECHANICAL VENTILATION 
Treatment of ARDS consists of mechanical ventilation to aid in lung recovery, oxygen delivery 
and carbon dioxide removal, while the underlying medical condition is also treated. Patients are 
often sedated into a drug-induced coma to ensure maximal oxygenation of vital organs. The 
mechanical ventilator forces oxygen into the lungs at concentrations that will maintain patient 
saturated oxygen content of the blood (SaO2) levels of greater than 95%. [10]. Mechanical 
ventilation relieves the pulmonary musculature and diaphragm, which would otherwise fatigue in 
an effort to supply oxygen to the body [7, 8]. 
 Mechanical ventilation can be damaging to the lungs after prolonged use. Extended 
support cannot be maintained without the risk of mechanically induced tissue damage from 
supraphysiologic airway pressures, as well as biologically induced tissue damage from high 
oxygen concentrations [7, 8, 11-13]. Ventilation is performed either with a fixed tidal volume or 
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a fixed pressure applied to fully ventilate the lungs. Lungs of ARDS patients require 
substantially higher pressure settings in comparison to healthy lungs due to lower dispensability 
of the pulmonary tissue [8, 9].  Volutrauma is one of the most common complications resulting 
from mechanical ventilation of ARDS patients. This condition arises from over expansion of the 
alveoli, and may be reduced by decreasing the tidal volume [8]. However, healthier areas of lung 
tissue will be distended much further than damaged or fibrosed lung tissue due to lower 
compliance, resulting in over-distension of the healthy tissue [9].  Pneumothorax may also occur 
in patients as a result of high ventilator pressure or volume settings. This condition is the product 
of lung tissue rupture from over expansion of the alveoli. In combination, high volumes and 
pressures from mechanical ventilation lead to enhanced edema in the injured lung [8]. 
Barotrauma may occur with increased ventilator pressures. Other complications include bacterial 
infections and multiple organ dysfunction or failure. 
 The high mortality rate associated with ARDS is linked to multi-organ failure, rather than 
hypoxemia [9]. There is evidence that mechanical ventilation may aggravate or even initiate 
pulmonary inflammation [14]. Proinflammatory cytokines, such as tumor necrosis factor (TNF)-
α, interleukin (IL)-1 and IL-6 are upregulated with hyperoxia and released during the initial 
phase of the inflammatory response [13]. Proinflammatory cytokines are elevated within 1 hr of 
conventional lung ventilation for ARDS patients [9]. In patients with healthy lungs, 
proinflammatory cytokines have not been shown to increase following 1 hr of conventional 
ventilation [9]. The inflammatory response becomes decompartmentalized following the rupture 
of alveoli and fluid leakage into the circulatory system, with systemic inflammation following. 
Septic patients experience a decline in levels of natural anticoagulants, such as  activated 
protein C (APC), antithrombin (AT) and tissue factor pathway inhibitor (TFPI) [14]. Tissue 
factor (TF, a membrane protein and coagulation initiator) is elevated in a septic patient, due to 
additional expression via monocytes and endothelial cells (ECs). The coagulation cascade is 
activated by the extrinsic pathway. Factor X is activated by TF, and the common pathway of 
coagulation is initiated [15].  Additional discussion regarding coagulation will be presented in 
subsequent sections. 
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1.3.1 Advancements in mechanical ventilation 
Significant effort is being directed toward improving outcomes with mechanical ventilation. 
Settings for mechanical ventilation may be fine tuned to reduce further lung damage. Positive 
end expiratory pressure (PEEP) is controlled to increase lung volume and keep alveoli open. 
Controlling PEEP also avoids excess oxygen delivery, which may further damage the lung. If 
PEEP is applied in small increments of 3 to 5 cm water, up to 15 cm, acceptable arterial oxygen 
saturation (≥0.9) may be achieved without further damage to the lungs [7]. PEEP has been 
documented to cause an increase in the functional residual capacity of the lung, which may be 
the result of the recruitment of collapsed alveoli [8]. Tidal volume controls the amount of air 
required to inflate the lungs [7]. Elevated tidal volumes may cause lung injury, including damage 
to the alveolar-endothelial barrier. The pulmonary capacity of ARDS patients is decreased, 
therefore tidal volumes as low as 6 ml/kg may be more appropriate than the conventional 12 to 
15 ml/kg.  
Techniques such as inverse-ratio ventilation and airway-pressure-release ventilation may 
also be employed for better patient outcomes. Inverse-ratio ventilation limits excessive airway 
pressures by increasing the inspiratory period to increase mean airway pressures. This process is 
most beneficial to portions of the lungs that are occupied by a non-homogeneous distribution of 
pulmonary infiltrates. However, inverse-ratio ventilation requires heavy sedation and/or 
paralysis. Additional randomized trials are necessary to demonstrate benefit prior to wide 
adoption of this method. This is also true for airway-pressure-release ventilation, which is 
designed to open and stabilize collapsed portions of the injured lung in patients that are capable 
of spontaneous breathing. Continuous positive airway pressure is applied in this technique. 
 
1.3.2 Pharmacological therapies 
Other alternatives to patient care involve pharmacologic therapies. Exogenous surfactant may be 
administered to substitute for the body’s own dysfunctional surfactants. Surfactants may improve 
air-space stability, and have antibacterial or immunologic properties [16]. Benefits from such 
treatment would include decreased airway pressures, improved ventilation and reduction of 
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nosocomial pneumonia. However, this treatment has not been proven effective to date [7, 8]. 
Corticosteroids were evaluated due to their ability to alter host inflammatory responses, but 
provided no benefit [7, 17]. Acetylcysteine, a thiol-containing compound, has the ability to 
scavenge oxygen free radicals, making it an attractive antioxidant for investigation. Trials 
revealed no increase in gas transfer or survival rate [7, 18]. Ketoconzoe inhibits thromboxane 
synthesis and leukotriene biosynthesis. It may prevent patients suffering from sepsis or multiple 
traumas from developing ARDS, but further investigation is needed [7, 19]. Alprostadil is 
another promising, but unproven option, which acts by blocking platelet aggregation, modulating 
inflammation and inducing vasodilatation [7]. Other vasoactive drugs, such as sodium 
nitroprusside, are used to enhance cardiovascular performance. Their ability to enhance 
vasoconstriction may improve gas exchange for ARDS patients, but current data are insufficient 
to draw conclusions [7, 20].  Pentoxifylline inhibits chemotaxis and activation of neutrophils in 
the animal model of sepsis. This phosphodiesterase inhibitor may prove beneficial in the future 
[7, 21]. The above mentioned drugs each display an element of possible therapy for ARDS 
patients, but further investigation and coupling of such drugs must first be accomplished.  
1.3.3 Nitric oxide 
Inhaled nitric oxide (NO) is a promising adjunctive treatment for ARDS. This gas acts as a 
selective pulmonary vasodilator at concentrations of 2 ppm to 40 ppm, and actively binds to 
hemoglobin for quick inactivation [22-24]. Inhaled NO has been shown to have negligible toxic 
effects when administered at 50 ppm for less than 7 hours. At high concentrations of greater than 
80 ppm, inhaled NO displays pro-inflammatory and pro-oxidant effects [25]. Continuous 
administration of NO consistently reduces pulmonary-artery pressure, but long term effects of 
such treatment have proven to be inadequate [7]. Patients that acquired ARDS from direct lung 
injury have responded more favorably to inhalation of NO than patients with indirect lung injury 
resulting in ARDS [25]. However, correct dosing of NO remains unclear.  
Gerlach et al. suggest that NO may be more beneficial if the dose is reduced over time, or 
administered intermittently [26]. Low doses of exogenous NO may be most beneficial in the 
early stage ARDS for short durations [27]. Anti-inflammatory benefits have been reported after 
exposure to low levels of ambient NO within hospitals, ranging from 2 ppb to 550 ppb [24]. 
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Respiratory repair is promoted through a reduction of leukocyte accumulation within the lungs. 
Inducible nitric oxide synthase (iNOS) and endothelial nitric oxide synthase (eNOS) are both 
often upregulated in response to hyperoxic conditions. iNOS-derived NO is believed to be anti-
inflammatory in hyperoxic lung injury [28]. NO is synthesized by the conversion of L-arginine 
to L-citrulline by nitric oxide synthase (NOS) [29]. However, Potter et al. found no pathologic 
benefit from this activity, in mouse pup lungs [30]. There are notable benefits of inhaled NO 
therapy, yet correct administration remains unclear.  
 
1.4 EXTRACORPOREAL MEMBRANE OXYGENATION 
In the advanced disease state, ventilators become inadequate, which leads to the addition of 
Extracorporeal Membrane Oxygenation (ECMO) in many cases. ECMO, using blood 
oxygenators designed for acute open-heart procedures, offers an alternative method for gas 
exchange [2]. ECMO is achieved by pumping patient blood through an extracorporeal circuit, 
which transfers oxygen and carbon dioxide to and from the blood and gives the natural lungs 
time to heal. The patient is often cannulated at the femoral vein. Blood travels through the circuit 
with the help of a peristaltic or centrifugal pump, and is forced through an oxygenator. At this 
point, carbon dioxide is removed and oxygen is added. The blood is subsequently exposed to a 
heat exchanger to elevate the temperature before re-entry through the femoral vein [6]. 
Oxygenators currently utilized for ECMO are often composed of microporous hollow 
fibers (MHFs). Oxygen flows through the lumen of the fiber and blood flows around the outside 
of the fiber. Gas passes through pores of the MHFs, rather than the membrane material, making 
membrane resistance to gas transfer negligible [31]. Such oxygenators are designed for short-
term use of 6 to 12 hours, in applications such as coronary artery bypass grafting surgery. 
Sustained use for ARDS patients leads to additional complications through blood-surface 
interactions, which can make the treatment no more favorable than mechanical ventilation. These 
fibers are functionally limited by plasma weeping, and biocompatibility issues associated with 
thrombogenesis. Plasma weeping is the penetration of liquid into the fiber pores, which inhibits 
gas exchange. Platelets deposit on the fiber surfaces and aggregate, also inhibiting gas exchange. 
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High levels of heparinization are required to reduce the risk of thrombus formation and the 
potential for thromboembolic events. Unfortunately, aggressive anticoagulation also leads to an 
increased risk of bleeding and further complications [32]. 
1.4.1 Microporous hollow fiber membranes 
Oxygenators utilizing MHF technology are overwhelmingly made from polypropylene (PP) 
MHFs. PP has a higher gas permeability through pores than other relevant polymers, such as 
silicone or silicone coated membranes, it has high strength relative to microporous silicone and 
other polymers, and it is easily sterilized by ethylene oxide gas [33].    PP fibers are produced by 
leading companies such as, AKZO-NOBEL (Netherlands), Mitsubishi Rayon (Japan), Celgard 
(Charlotte, NC), and Terumo (Japan), and will vary in physical characteristics based upon the 
manufacturer [2, 33].  
The structure of MHFs somewhat imitates the structure of capillaries found in the lung in 
vivo. Both a MHF and a glomerular capillary exhibit cylindrical cross-sections, and have similar 
wall thickness to cross-sectional diameter ratios. The cylindrical shape minimizes perimembrane 
boundary layers to increase transport efficiency [34]. Membrane pores allow gas exchange to 
occur through diffusion [2]. As mentioned, respiratory gases pass through the membrane pores 
rather than the membrane material [31]. The membranes are hydrophobic to discourage blood 
from entering into the pores [35]. 
Ideal membrane characteristics have been projected as follows: an effective permeability 
for oxygen and carbon dioxide should be present, water should not be passed in its liquid form 
by the membrane, and blood components should not be damaged by the membrane surface (i.e. 
possess thromboresistance and minimal chemical reactivity) [36].  
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1.4.1.1 Microporous hollow fiber membrane permeance  Diffusion across the MHF 
membrane is dependent on the area and thickness of the membrane [37]. Pore diffusion for 
MHFs can be described by Knudsen diffusion of gases in cylindrical pores. Gas molecules will 
collide more frequently with each other if the pore diameter (dpore) is less than the mean free path 
length of the diffusing species (λ), and the density of the gas is low [38]. The Knudsen number 
(Kn) is given in Equation 1 [38]. 
 
Equation 1 Knudsen Number 
Kn = λ/dpore
 
 The gas exchange permeance (K) is a measure of the rate of gas exchange for O2 or CO2. 
Km is the diffusional resistance of the MHF membrane, and is given in Equation 2, when 
Knudsen diffusion is assumed. Km is a function of porosity (ε), pore diameter (dp), pore 
tortuosity (τ), fiber wall thickness (h), molecular weight of the given gas (M), the gas constant 
(R) and absolute temperature (T) [2].  
 
Equation 2 MHF membrane permeance for Knudsen diffusion 
MRTh
dK pm πτε
22=  
 
A membrane permeability of Km~10-2 mL/cm2/s/cmHg should provide efficient gas 
exchange capacity. Mitsubishi KPF fibers have been measured at Km = 6.7x10-2 mL/cm2/s/cmHg 
in a gas-gas environment, where gas is forced through an individual MHF of know surface area, 
causing the gas to permeate through the membrane [35, 39]. Celgard X30-240 polypropylene 
fibers have been measured in gas-gas tests at Km=1.72x10-2 mL/cm2/s/cmHg and Km=1.4710-2 
mL/cm2/s/cmHg for O2 and Co2, respectively [35]. As a result of in vivo effects, this is not the 
case. 
The permeance is inversely related to the resistance. The overall transfer resistance for a 
blood oxygenator is given in Equation 3 as 1/K [2, 39].  
 
Equation 3 Gas transfer resistance 
1/K = 1/Km + 1/Kl
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 The inverse of Kl is the liquid-side transfer resistance from diffusional boundary layers. 
Kl is a function of the effective solubility coefficient of the diffusing gas (α), the diffusion 
coefficient of the diffusing gas (D) and the average boundary layer thickness (δ) for blood 
(Equation 4) [2]. 
 
Equation 4 Liquid side permeance 
bl
ll
l
DK δ
α=  
 
For PP MHFs Km is much greater than Kl, causing Km to be negligible, and reducing the 
gas transfer resistance to essentially 1/Kl. If composite or coated hollow fibers are employed, Km 
may play a significant role in overall transfer resistance. Composite and coated hollow fibers 
require the gas to diffuse through the polymer (p) material instead of micropores. Km for 
composite fibers is given in Equation 5 [2].  
 
Equation 5 Composite hollow fiber permeance 
p
pp
l
DK δ
α=  
1.4.1.2 Microporous hollow fiber membrane failure  The main chronic failure mode for MHFs 
used for ECMO is plasma wetting. Phospholipids, lipoproteins and/or proteins from blood adsorb 
onto the blood-contacting surface of the MHF [2]. The hydrophobic barrier, used to minimize 
plasma wetting, becomes hydrophilic as a result. In the absence of the hydrophobic barriers, 
plasma penetrates the fiber pores, because diffusion of gas species through a liquid is orders of 
magnitude lower than in gas. Diffusion of oxygen and carbon dioxide molecules is hindered by 
this hydrophilic membrane alteration [31, 35]. Overall gas exchange rates will ultimately decay, 
and the oxygenator will require replacement in as little as 4 to 12 hours following blood contact 
[35] [2]. Membrane permeance for liquid filled pores of MHFs is given in Equation 6 [2]. 
 
Equation 6 Membrane permeance for liquid filled pores of MHFs 
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αε=  
 
 
The hemostatic mechanism designed to stop bleeding in an injured blood vessel is also 
employed in response to a foreign body, such as the large blood contacting surface area of MHFs 
[40]. The meniscus, formed on the membrane pore at the blood/gas interface, is site susceptible 
to protein adsorption, leading to thrombotic deposition and poor biocompatibility [34]. When 
blood contacts the membrane, coagulation factors and proteins, such as factor XII, factor VII, 
vWF, fibrinogen, albumin, hemoglobin, and gamma globulin, deposit [41]. Protein adhesion 
varies depending on the surface properties. Free energy, surface roughness and/or chemical 
composition can influence quantity or type of protein adsorption.  
Platelet adhesive receptors, glycoprotein IIb/IIIa and glycoprotein Ib, interact with 
absorbed proteins to mediate platelet adhesion [40]. Platelets are non-nucleated disc shaped cells 
designed to arrest bleeding through formation of platelet plugs and catalyze coagulation reactions 
which lead to fibrin formation. Upon activation, platelets change in morphology to spiny spheres 
and extrude granule contents. Release of dense granule ADP, formation of thrombin, and 
biochemical activation of platelets leading to the generation of thromboxane A2 occurs following 
platelet adhesion [42]. Additional platelets are recruited to the site of activation to form a platelet 
aggregate through calcium dependent binding of adjacent platelets by fibrinogen molecules, and 
thrombin binding to membrane receptors.  Platelet aggregation leads to platelet procoagulant 
activity, such as expression of membrane phospholipids. Membrane phospholipids accelerate 
factor X activation and the conversion of prothrombin to thrombin, two critical processes in 
blood coagulation. Thrombin forms rapidly on the surface of aggregated platelets, activates more 
platelets and generates polymerizing fibrin[15]. The large surface area of ECMO circuits on 
which platelet deposition occurs, and heparin therapy can lead to thrombocytopenia [43-45]. 
The function of leukocytes and erythrocytes in thrombus formation is less explicit than 
that of platelets. Activated platelets expressing p-selectin will attract leukocytes through rolling 
interactions. Leukocytes will also adhere to platelet-bound fibrinogen in a haemostatic plug, or 
thrombus [46]. An association between leukocytosis and thrombotic complications has been 
shown in several clinical studies [46]. Erythrocytes will add to thrombus mass, but are generally 
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thought to play a passive role [15, 42]. However, in vitro work by Hellem et al. and Siniabiadi et 
al. has shown that erythrocytes enhance platelet aggregation by their tumbling nature in blood 
flow which generates a redial platelet gradient, increasing the platelet concentration at the 
boundary wall. In addition, high hematocrit results in higher blood viscosity and a higher 
residence time for circulating platelet factors and coagulation factors near the thrombotic site 
[47]. Research is ongoing to clearly define the roles of leukocytes and erythrocytes in thrombus 
formation associated with foreign body response. 
Thrombus formed from a combination of interactions between the surface, platelets and 
coagulation proteins may be enzymatically degraded by fibrinolysis [15, 48]. The fibrinolytic 
system is designed to facilitate healing following inflammation by removing fibrin deposits. 
Tissue plasminogen activator is released from ECs in the blood vessels following stimulation by 
thrombin, or may be introduced therapeutically through pharmaceutical agents [15, 49]. The 
fibrinolytic enzyme, plasmin, is found bound to fibrin/fibrinogen, or circulates in the inactive 
form as a protein plasminogen. Plasminogen is activated by plasminogen activators to digest 
fibrin clots, in the bound form, or impair platelet binding and aggregation, in the circulating form 
[41]. Upon digestion, soluble fibrin/fibrinogen digestion products, such as fibrin degradation 
products and D-dimer, are released into circulating blood [15, 41]. Studies have found decreases 
in the activation of the fibrinolytic and inflammatory systems following the administration of 
antifibrinolytic compounds, such as the serine protease inhibitor aprotinin, during 
cardiopulmonary bypass procedures employing oxygenators primarily composed of MHF 
membranes [48, 50].  
Anticoagulants are given prior to cardiopulmonary bypass surgery, or during ECMO, to 
attempt to minimize thrombus formation associated with blood contact to a foreign surface. 
Heparin is most commonly used for anticoagulation, since the effects of the drug can be 
neutralized with the administration of protamine. Heparin binds antithrombin III and amplifies 
its potency by a factor of 1000 to effectively inhibit thrombin and factors IXa, Xa, XIa, and XIIa. 
However, post-operative bleeding is of concern following oxygenator withdrawal [41, 48]. A 
balance in the management of therapeutic agents, such as heparin, protamine and aprotinin, and 
the coagulation and fibrinolytic pathways must be maintained to limit complications associated 
with hemostasis, particularly when ECMO is employed.   
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1.4.2 Standard blood oxygenators and microporous hollow fibers 
As mentioned above, the natural lung basal carbon dioxide removal is 240 mL/min and oxygen  
consumption is 270 mL/min. Oxygenators generally provide approximately 40% of the basal 
needs. A well-developed design may provide 135 mL/min oxygen and 120 mL/min of carbon 
dioxide transfer, acting at 50% efficiency [2]. Current oxygenators can perform consistently for 
six hours during cardiopulmonary bypass. Oxygenators are generally limited to one-day use, but 
can possibly last for several weeks before failure due to poor gas exchange and noticeable 
thrombus formation occur [15].  
Table 1 presents a list of commercially available oxygenators with PP membranes, the 
most commonly used MHF membrane for adult respiratory support [37]. Surface area varies 
between each model, ranging from 1.7 m2 to 2.5 m2 [37].  
 
Table 1 Nine MHF oxygenators 
Comparison of surface area and priming volume [37] 
 
 
The Affinity NT (Medtronic, USA) and Quantum (Bard Inc., Haverhill, MA, USA) 
oxygenators were found to produce the best oxygen transfer of these nine, based on clinical 
findings in patients undergoing coronary bypass surgery, with statistically significant differences 
of p<0.01 and p<0.05, respectively [37]. Table 2 compares the percent hemoglobin and platelet 
numbers between the above mentioned nine oxygenators. Oxygenators were evaluated during 
patient support in cardiopulmonary bypass procedures for 1-1.5 hrs. Hemoglobin and platelet 
numbers were taken pre- and post-operatively, hence % decrease is shown in the table in 
comparison to pre-operative values. The data are notable in that little difference is observed 
across various models. 
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Table 2 Hemoglobin and platelet levels in nine MHF oxygenators 
Shows a decrease in hemoglobin and platelets in the first postoperative samples compared to  preoperative 
values [37]  
 HB (% decrease) Platelets (% decrease) 
Maxima 70 ± 9 65 ± 21 
Forte 74 ± 13 67 ± 16 
Affinity 78 ± 12 57 ± 11 
Affinity NT 72 ± 7 65 ± 15 
Quantum 70 ± 10 65 ± 12 
Capiox 75 ± 6 71 ± 10 
Optima 72 ± 7 70 ± 7 
Quadrox 71 ± 7 64 ± 11 
Hilite 71 ± 6 64 ± 13 
 
Gas exchange capability is dependent on multiple factors, including fiber bundling, fiber 
structure, winding of the fibers and flow pattern through the fiber bundles [37]. Many 
adaptations to fibers or fiber configurations have been presented to optimize flow and gas 
transfer characteristics. AKZO NOBEL (Germany) produces the MHFs, OXYRAY, made of 
polyethylene, and OXYPHAN, made of PP. Both have nearly identical properties to other PP 
MHFs, but processing techniques are different. OXYPHAN, a hydrophobic, microporous PP 
membrane is produced through a technique created by AKZO NOBEL. A thermally induced 
phase separation process homogeneously mixes the polymer with two natural seed oils. The 
product is then spun and cooled, resulting in a porous structure with consistent and uniform pore 
distribution (oil is removed). TERUMO (Tokyo, Japan) uses a similar process to AKZO 
NOBEL, using mineral oils. This produces less consistent pore size and distribution, and leaves 
the fiber more susceptible to plasma/blood leakage. Mechanical strength of this PP membrane is 
very low [33].  
Mitsubishi and Hoechst use a "drawing" process to create a net like structure of dense, 
unexpanded regions alternating with small ruptures (or pores) on polypropylene fibers. However, 
this process allows pores to penetrate the full depth of the membrane wall, allowing the 
possibility of plasma breakthrough or leakage to occur. Optima uses a microporous membrane 
from AKZO NOBEL, which it claims to exhibit high gas permeability, high resistance to plasma 
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breakthrough, and high tensile strength obtained from a cross-wound mat configuration [33].  
These are all key aspects in membrane performance. 
Surface modified MHF membranes are also clinically available and commonly used. 
Heparin-coatings, surface modifying additives (SMA) and poly-2-methoxyethylacrylate (PMEA) 
are examples of surface treatments applied to MHF membranes [51, 52]. Medtronic’s 
AFFINITY® NT oxygenator is available with covalently bonded heparin coatings of either 
Carmeda® (proprietary anticoagulant active sequence) or Trillium® (incorporates proprietary 
anticoagulant active sequence, sulphate and sulfonate groups to mimic the negative charge of 
endothelium, and hydrated polyethylene oxide polymer chains) (Medtronic, Minneapolis, USA) 
[53]. Baxter offers the Duraflow-II coating (Baxter Corporation, Irvine, CA), a heparin coating 
which uses an ionic process to attach heparin to the surface [54, 55]. SMARxT (COBE 
Cardiovascular Inc, Arvada, CO) is an example of an oxygenator utilizing the SMA copolymer 
[51]. The CAPIOX® RX (Terumo, Tokyo, Japan) is an example of an oxygenator utilizing 
PMEA [52]. SMA- and PMEA- coated circuits are more commonly used in cardiopulmonary 
bypass procedures than heparin-coated circuits, which are commonly employed in ECMO 
procedures. SMA and PMEA coatings aim to reduce contact activation during cardiopulmonary 
bypass, but the effectiveness of the surface modification is unclear. Some studies show clinical 
benefits, such as elevation of plasma anti-inflammatory IL-10 and urinary alpha-1-microglobulin 
48 hours postoperatively [56]. Other studies conclude that SMA- and PMEA-coated circuits do 
not improve platelet consumption or decrease blood product use for patients undergoing 
cardiopulmonary bypass procedures, but may still have some clinical benefit [52]. 
When heparin function is preserved on the surface of cardiopulmonary bypass or ECMO 
circuits, heparin coatings hold several advantages over non-coated surfaces. These heparin-
coated surfaces attenuate the system inflammatory response, and present a hydrophilic, protein 
resistant barrier to improve surface biocompatibility [57]. Contact activation, coagulation 
activation, complement activation and platelet and leukocyte activation (directly or indirectly) 
are attenuated [57-59]. Niimi et al. concluded that heparin coating of PP oxygenator fibers 
decreased platelet adhesion without affecting adsorption of major adhesive proteins [40, 44]. 
Studies involving use of Duraflow-coated cardiopulmonary bypass circuits concluded that lower 
activated clotting times (ACT) (e.g. ACTs of 300 instead of ACTs of 400) could be maintained 
with lower levels of systemic heparinization, and fibrinogen consumption was reduced [54, 60]. 
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Spiess et al. observed a reduction in tissue plasminogen activator (TPA) in patients undergoing 
coronary artery bypass graft procedures when a Carmeda (Medtronic Inc, Anaheim, CA) coated 
cardiopulmonary bypass circuit was employed [61]. Nonetheless, mortality rates still remain 
high in ECMO for ARDS patients, even though heparin-coated oxygenators are commonly 
employed. This provides motivation for the development of more biocompatible oxygenating 
devices.  
1.4.3 Mass transfer augmenting blood oxygenators 
Mass transfer augmentation is being explored in devices such as the chronic artificial lung 
(CAL), the paracorporeal respiratory assist lung (PRAL), and the pumping artificial lung (PAL). 
The CAL (formerly known as the Active Mixing Membrane Oxygenator, or AMMO) was 
developed at Ension, Inc. as an oxygenator and cardiac pump. It utilizes a spinning disc of PP 
fibers to oxygenate blood at a targeted blood flow rate of 4 L/min. The paracorporeal device is 
designed for up to 21 days of use with a targeted O2 efficiency of 500 mL/min/m2 and a targeted 
surface area of 0.5 m2 [62]. Currently, the prototype has a CO2 exchange efficiency of 370 
mL/min/m2 [63].   
 The PRAL is under development at the University of Pittsburgh, under Dr. William J. 
Federspiel, as an aid for acute lung failure. The prototype is composed of a bundle of PP MHF 
membranes with gas exchange area of 0.25 m2. At test speeds of 1500 RPM the device could 
generate 750 mL/min fluid flow against 52 mmHg pressure, remove CO2 at a rate of 256 ± 16 
mL/min/m2, and provide O2 at a rate of 206 ± 11 mL/min/m2. Minimal erythrocyte damage was 
shown, but an increase in plasma free hemoglobin was noted [64].   
The PAL, manufactured by Makarewicz and Mockros, also employs annular rotation of a 
MHF bundle.  A modified Biomedicus BMP-50 pump head houses the MHFs to give a surface 
area of 0.6 m2. CO2 can be removed at a rate of 125 mL/min/m2 and O2 can be provided at a rate 
of 119 mL/min/m2 for in vitro testing using saline at flow rates of 7 LPM. However, gas 
exchange was independent of rate of fiber bundle rotation [65, 66].  
All three of these devices are in pre-clinical phases, but provide innovative designs that 
may lead to significant improvements in oxygenation for acute lung failure patients. This 
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ongoing research reflects an effort to improve blood biocompatibility, O2 delivery and CO2 
removal.  
1.4.4 Ongoing research for improved oxygenator biocompatibility 
Ongoing research for improved blood biocompatibility, O2 delivery and CO2 removal is not 
limited to overall oxygenator design. The use of coated and alternative hollow fiber membranes 
is also being explored. Groups are using siloxane coatings and/or heparin surface treatments in 
designs for possible device improvement. Niimi et al. coated a capillary membrane oxygenator 
with less than 2μm of silicone. This design resulted in less trauma to blood components and 
reduced thrombogenicity than in PP fibers, which was attributed to surface smoothness [67]. Iida 
et al. found their coating of less than 2μm silicone to be better for long-term cardiac support, in 
addition to cardiopulmonary bypass surgery applications [68]. The silicone film also prevents 
plasma infiltration of the pores, which contributes to a longer in vivo life span in comparison to 
PP fibers. PP fibers have more adverse effects on blood elements than silicone coated 
membranes, resulting in higher plasma free hemoglobin content in the blood. Yet, plasma free 
hemoglobin levels have been shown to be very low for non-coated fibers in general [37, 67]. 
Niimi et al. also found platelet adhesion was reduced without affecting adsorption of major 
proteins, by covalent attachment of heparin to the fiber surface. They concluded that heparin 
coating combined with low dose heparinization can reduce platelet adhesion and activation to 
potentially reduce the inflammatory response, thrombosis and fibrinolysis [40, 44].  
Other groups have investigated alternative hollow fibers for use in oxygenators. Maeda et 
al. developed a silicone membrane hollow fiber oxygenator and compared it to the commercially 
available Kolobow (Avecor 1500, Medtronic Inc., Minneapolis, MN) silicone oxygenator, 
finding superior efficiency and less blood trauma [69]. Nonporous membranes of silicone, like 
that found in the Kolobow, have advantages such as less damage to blood and longer clinical life 
span [36]. Toomasian et al. provided extracorporeal life support to sheep on a long term gas 
exchange device made of polymethylpentene (PMP) fibers for 72 hours without plasma leakage 
[70]. PMP fibers have an asymmetric pore structure and dense outer skin that inhibits direct 
contact of blood and gas across a micropore [70]. Niwa et al. has developed a membrane 
oxygenator composed of novel asymmetric polyimide hollow fibers [71]. Often a compromise is 
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made between gas exchange capabilities and blood-surface biocompatibility with these new 
technologies. 
Additionally, endothelialization of MHFs is being investigated. The addition of ECs 
could be very useful since they may reduce anticoagulation therapy, limit fiber wet out, provide 
an additional diffusion barrier, and produce nitric oxide and surface heparin. Negative factors 
may include risk of inflammation state causing coagulation, interaction with the immune system 
and surface retention difficulties [44]. Takagi M et al. have endothelialized PP MHFs to create a 
hybrid artificial lung. MHFs were covalently bonded with fibronectin to maintain a high EC 
density, even in the presence of a shear force of 1.15 N/m2. A cardiopulmonary bypass system 
was made from 150 endothelialized MHFs of 8 cm length to support in vivo extracorporeal 
support of Sprague-Dawley rats for 60 minutes. In comparison to blood bypassed over untreated, 
non-endothelialized polypropylene MHFs, concentrations of IL-10 (an inflammatory inhibitor) 
increased and TNF-α (proinflammatory factor) decreased [72].  
The need remains to provide adequate gas transfer and limit adverse affects associated 
with oxygenators. Although silicone and heparin coatings may provide some advantages over 
current models, more work needs to be done to address biological, chemical and mechanical 
requirements associated with artificial oxygenation. Use of lower levels of anticoagulants would 
likely benefit the patient’s overall hemostasis, which may be achieved with certain MHF 
coatings. Even if reduction of anticoagulation therapy can be accomplished safely, a profound 
need for chronic respiratory support remains. Issues associated with high levels of 
anticoagulation, bleeding, fiber wet out and thrombosis persist as critical limitations for patients 
requiring chronic respiratory support. 
1.5 EC CONSIDERATIONS 
1.5.1 EC inflammatory phenotype 
A hemocompatible, non-inflammatory EC phenotype contributes to maintaining the proper 
balance between thrombosis and fibrinolysis [41]. There are multiple EC products that regulate 
hemostasis. Prostacyclin is a vasodilator and inhibitor of platelet aggregation. Nitric oxide is also 
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secreted as an inhibitor of platelet aggregation and adhesion, and acts as a vasodilator. 
Ectonucleotidases are surface enzymes that regulate the breakdown of platelet-active and 
vasoactive nucleotides. Thrombomodulin is expressed on the surface of ECs to act as an 
anticoagulant. Tissue factor pathway inhibitor is synthesized by ECs to inhibit tissue factor, a 
procoagulant. Type I plasminogen activator inhibitor (PAI-I) is a secreted, circulating and 
matrix-bound inhibitor of tissue plasminogen activator, a fibrinolysis initiator [73]. ECs express 
heparin sulfate on their surface, which can remove potential agonists and reduce the possibility 
of focal platelet activation [74].  
Avoiding entrance into an inflammatory EC phenotype is crucial for maintaining an 
antithrombogenic endothelialized MHF surface. Activation of the endothelium results in 
recruitment of platelets and leukocytes to the activated site [74, 75]. The membrane of an EC 
contains multiple adhesion receptors, such as integrins, cadherins, cellular adhesion molecules 
(CAMs) of the immunoglobulin superfamily and selectins. ECs expressing p-selectin support 
transient interactions with platelets [76]. And secretion of von Willebrand factor (vWF) from 
ECs can lead to adhesive interactions of platelets [74, 77]. E-selectin is associated with tethering 
and rolling interactions leading to adhesion of leukocytes [76, 78]. Platelet EC adhesion 
molecule-1 (PECAM-1, CD31) is related to inflammation through its involvement in 
extravasation of leukocytes and has also been shown to increase thrombosis in the vasculature 
when upregulated [79]. Intracellular adhesion molecule-1 (ICAM-1, CD54) is expressed on the 
membrane of ECs and binds to integrins (CD11 a & b) present on neutrophils and macrophages 
when upregulated. Vascular cell adhesion molecule-1 (VCAM-1, CD106) is also expressed by 
ECs and regulates the adhesion of monocytes, basophils and eosinophils through integrin 
(CD49d/CD29) binding [80]. Tissue factor (thromboplastin) is expressed as a procoagulant on 
activated endothelium. Platelet-activating factor is platelet and leukocyte agonist, which is both 
surface-expressed and secreted by ECs [73].   
1.5.2 Coatings for EC attachment 
Cell retention may be improved on artificial surfaces by implementing engineered approaches, or 
adding biologically adhesive proteins to the substrate [81, 82]. Arg-Gly-Asp (RGD, amino acid 
synthetic peptide for cell attachment-promoting activity), Arg-Gly-Asp-Ser (RGDS, amino acid 
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synthetic peptide for cell attachment-promoting activity), Fn-like (a fibronectin-like engineered 
peptide containing binding sequences), biotin (a water-soluble vitamin), a combination of biotin-
avidin (the combination increases thermal stability of binding and promotes structural order), 
1,4-diiscocyanate butane (BDI, provides a chemical link to improve protein binding stability) , 
polyethylene glycol (PEG, provides a chemical link to improve protein binding stability), 
pronectin (an adhesion peptide with multiple copies of the human fibronectin RGD attachment 
domain), etc. are examples of spacers or cell adhesive peptides that have been used to enhance 
protein adsorption and EC attachment [83-87]. Collagen, matrigel, gelatin, and fibronectin are 
commonly applied proteins to aid in EC attachment. These proteins can be found in the 
extracellular matrix below the monolayer of ECs lining blood vessels in vivo, and therefore make 
desirable candidates for in vitro EC attachment as well [72, 88].  
 Engineered approaches, or protein adsorption approaches to cell adhesion have been 
shown to promote cell-surface growth and compatibility. Wang et al. found gelatin- and RGD- 
modified polyurethane surfaces promoted human umbilical vein EC (HUVEC) growth [89]. 
Numerous groups have also shown increased cell attachment to polymer surfaces when 
combined engineered and/or protein adsorption methods are used. Chung et al. showed an 
increase of 8.5 times for HUVEC growth on a poly(epsilon-caprolactone)-PEG-RGD surface in 
comparison to a poly(epsilon-caprolactone) surface without modification [90]. Zhu et al. 
modified polyurethane surface with diamine and covalently grafted it with gelatin to promote 
HUVEC growth [91].  
Plasma glow discharge may be applied to surfaces to enhance protein adsorption and EC 
attachment as well [92]. Pratt et al. showed a synergistic effect between fibronectin and plasma 
discharge treated polyethylene terephthalate films that greatly enhanced EC attachment [93]. To 
perform plasma discharge, the material is placed in a chamber, a gas source is pulled through the 
chamber under vacuum and plasma is discharged with an electrical current onto the material 
surface [94]. Air, oxygen, water and ammonia are common sources for plasma discharge. If 
ammonia gas is selected as the source, for example, amine groups will attach to the surface. With 
ammonia plasma discharge, surface hydrophilicity will increase [95].   
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1.5.3 Shear stress exposure 
Numerous studies have been conducted for laminar flow across endothelialized cover slips, or in 
other 2-D models. Far fewer studies have been conducted in 3-D models. However, both types of 
experiments have observed EC alignment under the influence of shear through cytoskeletal 
rearrangement [96]. EC alignment has been shown to occur at 10 dynes/cm2 under unidirectional 
steady laminar flow within 7-9 hours by Davies et al. [97]. Davie et al. also showed that ECs 
subjected to laminar shear stresses from 8-15 dynes/cm2 over 24 hours aligned in the direction of 
flow without entering the cell cycle [98]. However, with turbulent shear stresses at 1.5 dynes/cm2 
for 3 hours, EC DNA synthesis in the absence of cell alignment, cell retraction and/or cell loss 
were observed [98]. The EC response to shear is both magnitude and flow pattern dependent 
[99]. In addition, cell function, morphology and gene expression is altered with exposure to fluid 
shear stress [100].  Under chronic shear stress, ECs flatten, structurally remodel to spread the 
shear stress over greater surface area and therefore increase adherence to the substratum through 
focal contacts [101]. Increased stress fiber formation was shown in flow preconditioned 
HUVECs [81].  
The well defined flow environments of parallel plate chambers and cone-plate 
viscometers do not provide exact replicas of the shear stress environment that ECs may 
encounter in an active mixing oxygenator. Blood may be assumed to be a Newtonian fluid as 
long as moderate to high shear stresses are maintained. In areas of low shear stress, or potential 
stagnant areas of an oxygenator, blood may behave as a non-Newtonian fluid [102]. ECs in vivo 
are exposed to secondary flow patterns, depending on location in the blood vessel [102]. Active 
mixing oxygenators may provide secondary flow patterns as well due to the nature of the mixing, 
yet insufficient characterization of the influence of flows has been performed to elucidate the 
potential adverse effects on ECs. 
It has been demonstrated that levels of VCAM1, ICAM-1, PECAM-1, e-selectin, p-
selectin, and TF can increase with fluid flow [77-80, 102-105]. It has also been observed that 
laminar shear stress appears to protect ECs from inflammatory responses, by inhibiting tumor 
necrosis factor (TNF)-α, and EC proliferation, and by inducing growth arrest proteins such as 
GADD45 and p21 [99, 106, 107]. Lack of cell proliferation with increased shear stress is 
attributed to the inability of the cell to enter into the S-phase, which affects the overall cell 
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cycle[102]. The behavior of ECs will be observed within the scope of this project, to determine if 
CAMs and selectins are upregulated in response to shear stress, or protected by it. 
 
1.5.4 Hyperoxia and ECs 
Hyperoxia has been shown to have deleterious effects on ECs. Patients receiving mechanical 
ventilation as treatment for ARDS may be exposed to 100% oxygen at times. Such high levels of 
oxygen have an adverse effect on inflammation and coagulation. Capillary ECs are susceptible to 
oxygen toxicity, which leads to structural alterations. Platelets accumulate within the 
microvasculature of the lungs, followed by neutrophil accumulation. Upregulation of CAMs is 
observed in early stages of oxygen toxicity damage. PECAM-1 is a signal transducer expressed 
at junctions between ECs, and is necessary for transendothelial migration of leukocytes [108]. 
Multiple isoforms of PECAM-1 may be presented by ECs. These isoforms elicit different roles, 
including an early role in the inflammation cascade [108, 109]. Piedboeuf et al. found significant 
increases in PECAM-1 mRNA within 48 hours of exposure to 100% oxygen, in mice. This 
coincided with the appearance of leukocytes in the lung tissue. Additionally, the PECAM-1 
expression was found mostly on ECs, and less abundantly on platelets and leukocytes [108].  
ICAM-1 mRNA levels were significantly elevated within 48 hours of exposure to oxygen 
at levels of 95% or greater as well, in mice in vivo. Alveolar epithelial cells were the primary site 
of ICAM-1 production [108, 110]. Welty et al. reported increased neutrophil adhesion and 
transmigration following increased expression of ICAM-1 expression on ECs stimulated by 
inflammatory cytokines in mice in vivo [13].  But, DeLisser et al. suggests that neutrophil 
recruitment may occur independently of ICAM-1, based on in vivo experiments with mice [109]. 
Nonetheless, it is believed that multiple CAMs are involved in leukocyte and neutrophil 
recruitment in the above mentioned hyperoxic mouse models [108]. 
Barazzone et al. showed how a combination of changes in CAMs and cytokine levels can 
lead to platelet sequestration, detectable in mouse lungs following 72 hours of 100% O2 
exposure. ICAM-1 and TNF-α levels increased significantly, as shown by Northern blots of 
mRNA followed by the platelet entrapment. Platelet deposition decreased in response to TNF 
antagonist and anti-CD11a monoclonal antibody [110]. 
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Hyperoxia affects other factors in addition to CAMs. Inflammatory cytokines, such as 
TNF-α and interleukin-6 (IL-6) are upregulated [13]. Overproduction of PAI-1, which impairs 
fibrinolytic activity, has been demonstrated in mice lungs [111]. Perkowski et al found an 
increase in p21 expression (relevant to inhibition of cell cycle progression), an increase in BcL-
XL (an anti-apoptotic gene), an increase in reactive oxygen species (ROS), a decrease in BAX (a 
pro-apoptotic gene), and a decrease in thrombomodulin, following 48 hour exposure to greater 
than 95% O2 [112]. Downregulation of thrombomodulin may contribute to activation of the 
inflammatory and coagulation cascades. Inflammatory reactions have been shown to cause 
oxidative damage as well, more specifically, activated leukocytes release ROS such as H2O2, 
NO, O2-, OH and HOCl [113]. An increase in ROS can lead to an increase in cytokines (e.g. 
TNF-α), chemokines (e.g. IL-8) and CAMs (e.g. ICAM-1). Increased ROS expression also 
causes DNA fragmentation, changes in EC metabolism and permeance, crosslinking of 
membrane proteins, and peroxidation of lipids and inhibition of cellular phosphates. In essence, 
increased ROS can cause direct EC damage [112, 114, 115]. 
1.6 THE BIOHYBRID LUNG APPROACH 
1.6.1 Significance of the biohybrid lung 
Current oxygenation devices lack suitable long term support capabilities. Such devices fail to 
incorporate a vital biocompatible surface that could rectify biocompatibility issues associated 
with long term support. The following chapters will describe the development of a biohybrid 
lung prototype. The biohybrid lung prototype seeks to provide a biocompatible surface for long 
term ECMO support for ARDS patients. By endothelializing MHFs that constitute the major 
blood contacting surface area of the device, the biohybrid lung prototype seeks to greatly reduce 
or eliminate the need for chronic anticoagulation or anti-platelet agents. The attached endothelial 
layer provides a naturally occurring biocompatible surface for blood interaction if the cells are 
maintained in a non-inflammatory, anti-thrombotic phenotype.  
Oxygenator (in reality, gas exchange device, oxygenator is a misnomer) exchange is a 
common complication associated with ECMO support, and leads to blood product consumption 
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and further complications. Oxygenator change-out is required after plasma weeping and platelet 
deposition have significantly degraded gas transfer within the device. Providing a biocompatible 
surface to reduce or eliminate the need to perform oxygenator exchange would offer 
considerable benefit to ECMO patients. The endothelial layer should act as a protective barrier to 
decrease plasma weeping and platelet deposition. The enhanced biocompatibility offered by the 
biohybrid lung may provide a solution to ARDS patients that would otherwise be unable to 
tolerate aggressive mechanical ventilation or traditional ECMO therapy. In addition, it may 
provide an improved quality of life to patients who may successfully undergo traditional 
therapies.  
The MHF bundle will rotate up to 1500 RPM to facilitate active mixing of the blood. 
Shear stresses fall in the physiologic range of less than 35 dynes/cm2. Active mixing may act to 
reduce the required surface area for adequate gas transfer and lower the burden of 
biocompatibility associated with a larger device. Although the EC layer may slightly decrease 
the gas transfer efficiency of the device, by increasing the diffusion length, this tradeoff is 
acceptable for the potential to substantially reduce thrombotic and plasma weepage 
complications. Oxygen levels will be elevated above normoxia (21% O2) to enhance oxygen 
delivery to the blood further reducing the required device surface area. 
The main focus of this research was to study the interaction of ECs within the fluid 
environment of the biohybrid lung for improved biocompatibility. Key questions of permissible 
shear stress, oxygen tolerance and platelet deposition were addressed. Some other important 
questions were not explored in the scope of this project. These issues include in depth evaluation 
of active mixing, CO2 removal and developing a practical cell harvesting protocol. Active 
mixing may minimize boundary layer effects, and could also lead to a decrease in the surface 
area requirements and overall size of the device. Relationships were not developed between 
active mixing experimentation and boundary layer effect reduction or device size. Oxygen 
transfer and accumulation data were collected experimentally to look at oxygen delivery with 
increased fiber bundle rotation rates. 
While one aspect of this project was focused on oxygen toxicity, CO2 removal was not 
investigated. Accumulation of CO2 may ultimately lead to cell death and long term device 
complications. Elevated levels of CO2 may cause changes in pH that are detrimental to cellular 
integrity. Therefore, CO2 removal is not a trivial issue. Passive diffusion may, or may not 
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provide a suitable means for CO2 removal. Sufficient alternatives for CO2 removal will not be 
addressed in this dissertation, but it is important to be aware of the impact that CO2 accumulation 
may have on this system. CO2 removal will need to be addressed at some point in the overall 
development of a biohybrid lung prototype before it can reach clinical trials. 
Another key issue not tackled in the scope of this project is EC harvest and expansion. It 
is envisioned that ECs will be harvested from a patient’s own peripheral source. This process 
may include venous sources or microvasculature in adipose tissue. The cells would be plated in 
culture, stimulated with EC specific growth factors and expanded to an appropriate cell seeding 
density. However, at this point in time there is value in first understanding the basic endothelial 
response to hyperoxia and elevated shear stresses in the context of a rotating MHF bundle. 
1.6.2 Surface modification of microporous hollow fiber membranes 
MHFs have been designed to limit cell adhesion, and thus, require surface modification to 
support EC adherence. Several surface modification techniques were evaluated to determine the 
appropriate treatment methodology. In order to compare surface treatments, patches of modified 
MHFs were evaluated for EC adhesion. Consideration was also given to possible consequences 
associated with blood contact onto areas of exposed surface treatment, should ECs not achieve 
confluence for all fibers or if cells were lost to detachment by shear forces or other phenomena. 
MHFs were anticipated to have subconfluent EC coverage.  
1.6.3 Specific aim #1: bioreactor development 
The model biohybrid lung, expected simulating conditions to occur in devices sufficient in size 
to provide adequate gas exchange for an adult, provided an appropriate environment to answer 
basic questions concerning EC retention and function without the financial and spatial demands 
of a full scale prototype. The biohybrid lung prototype is more of an overall concept, and the 
term bioreactor is used to describe the physical housing that centers round a removable, rotating 
MHF module, allowing for fluid and gas sampling. The bioreactor was designed to incorporate 
both fiber bundle rotation, and gas flow through the fiber lumen, while minimizing the use of cell 
culture supplies over a test period of up to 7 days. 
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Non-MHF module material interactions within the bioreactor were a key concern due to 
their possible negative influence on EC retention and device biocompatibility. Debris from seal 
or shaft wear or other material interactions can have a toxic effect on cells. Sufficient levels of 
debris may kill ECs or induce an inflammatory phenotype [15]. Material selection was therefore 
evaluated to avoid cytotoxicity. Metallic corrosion or wear could also lead to mechanical failure, 
which could result in loss of active mixing or loss of separation between gas and liquid 
pathways, for example. Maintaining system sterility was an additional challenge. Development 
of appropriate assembly techniques was crucial for maintaining sterility within the system. 
1.6.4 Specific aim #2: ECs conditioned to shear stress 
Endothelialized MHF bundles were conditioned to rotational shear stress in a normo-
physiological range and evaluated. A shear-conditioning regimen was developed to combat cell 
loss. It was hypothesized that ECs would have an upper bound for shear tolerance, that when 
exceeded would lead to cell dislodgement. It was also thought that a shear-training regimen 
would be needed to retain cells initially. Immediate exposure of ECs to shear stress has been 
shown to cause cell loss [21]. An initial period of static cell culture provides cells with an 
opportunity to firmly adhere to the surface.  
Some cell loss may occur while the module is being conditioned to shear and transferred 
to the bioreactor. This loss will be difficult to compensate for once rotational shear begins. From 
preliminary experiments, cells cease to proliferate following continuous exposure to shear stress. 
Therefore, it is important to reach nearly confluent levels prior to introducing the module into the 
bioreactor. It is believed that cell retention will decrease with increased rotational shear. This 
may not be apparent in the designated rotational range of up to 1500 RPM.  
It was also thought that ECs would be able to sustain physiologic rates of shear stress 
without detaching from the MHF bundle. Vascular ECs experience a range of shear stresses 
depending on location in vivo. The physiologic range of shear stress on vascular endothelium has 
been reported as 1 to 40 dynes/cm2 [20]. It is reasonable to use this range of shear stress as a 
guide for in vitro experimentation.  However, it is also possible that ECs will respond differently 
to lower or higher shear stresses in vitro than they would in vivo.  
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In order to evaluate endothelial response, e-selectin (CD62E), p-selectin (CD62P) and 
PECAM-1 expression was evaluated, as well as cell retention. ECs expressing an inflammatory 
phenotype often over express CAMs and selectins [77-79, 104, 105]. Jankowski et al. used flow 
cytometric techniques to measure expression of ICAM-1 and TF. They found an increase in TF 
on endothelialized grafts exposed to 2.5 dynes/cm2 for 6 hours, verses the static control. EC 
retention was not affected by shear exposure [35]. It was anticipated that there is a maximum 
shear level that may be achieved without losing cells or inducing inflammation. If an 
inflammatory phenotype is present, more conservative operating conditions may need to be 
established, which could involve less oxygen and/or shear to make the biohybrid lung feasible. 
1.6.5 Specific aim #3: thrombotic deposition and inflammation in the biohybrid lung 
prototype  
This aim sought to assess platelet deposition and EC inflammatory response to bovine blood 
introduced within the biohybrid lung prototype. Whole bovine blood was mixed in the biohybrid 
lung prototype for 2 hrs with non-surface modified, non-endothelialized MHF bundles or 
endothelialized, surface modified MHF bundles. Thrombotic deposition was subsequently 
evaluated under light microscopy or with SEMs. EC phenotype was evaluated for upregulation 
of e-selectin or p-selectin. It was hypothesized that an endothelialized surface would greatly 
reduce platelet attachment and thrombotic deposition on MHFs. The endothelial layer should 
provide a naturally occurring barrier that discourages thrombosis if a non-inflammatory EC 
phenotype was retained. Non-endothelialized, uncoated MHFs, found in commercial 
oxygenators, do not discourage thrombus formation, and were therefore expected to show more 
thrombotic deposition than endothelialized MHF bundles [116].  
There was additional concern that subconfluent areas of MHFs may promote platelet 
deposition for two reasons. One reason is that the amount of platelet deposition could be 
dependent on the applied surface treatment. For example, collagen has been shown to promote 
EC attachment, but it is also known to directly facilitate platelet deposition [117]. Fibronectin 
has also been shown to promote EC attachment, but the protein is not pro-thrombotic [93]. 
Thrombotic deposition would be anticipated on subconfluent areas of collagen treated MHFs, but 
not fibronectin treated MHFs. The second reason is that ECs in vivo present a continuous, 
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semipermeable barrier. ECs communicate through intracellular junctions to regulate permeability 
and maintain homeostasis [118]. Disruption of cell to cell contact could disrupt homeostasis. ECs 
that do not contact one another on MHFs may express an inflammatory phenotype that could be 
pro-thrombotic [104]. Several surface treatments were applied to MHF patches and varying 
levels of confluence were achieved. Thrombotic deposition, following whole blood incubation, 
was quantified to address concerns related to subconfluence.   
It was hypothesized that thrombotic deposition on subconfluent MHFs should not be 
statistically significantly higher than platelet deposition on confluent MHFs. If anticoagulation is 
required, the heparin concentration will likely be much less than that required for non-
endothelialized MHFs. Ideally, the device will not require any anticoagulation. However, 
minimal heparinization offers an acceptable alternative if this goal cannot be achieved.  
1.6.6 Specific aim #4: hyperoxia in the biohybrid lung prototype 
In light of all the undesirable effects associated with hyperoxia, endothelial response to high 
oxygen partial pressures in the MHF lumen was examined. ECs were evaluated for phenotype 
alteration under hyperoxic conditions within the biohybrid lung model. A rotating fiber bundle 
had oxygen perfused through the lumen of each fiber within the bioreactor. Gas transfer across 
the membrane exposed the EC monolayer to hyperoxic conditions. The EC phenotype was then 
assessed. 
It was expected that ECs would exhibit a certain level of tolerance to hyperoxia. There 
may be an upper limit to the oxygen partial pressures that are reasonable to utilize within the 
device. Barry et al. showed far less effect of oxygen toxicity for mouse lungs exposed to 85% 
oxygen, compared to 100% oxygen [36]. Many researchers have shown deleterious effects of 
hyperoxia on lung tissue and endothelium; however there appears to be a range of hyperoxia that 
will be tolerated for longer periods of time. ECs exposed to hyperoxia in vitro in tissue culture 
experiments did not show the same deleterious affects as ECs exposed to hyperoxia in the whole 
organ or in vivo [119, 120].  
It was also thought that oxygen delivery to the biohybrid lung might be limited by the 
presence of an EC layer. The rational was that coatings can present an added barrier for gas 
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transfer across the MHF membrane. The addition of an EC layer might potentially increase the 
permeance of the composite synthetic and biological membranes. 
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2.0  SURFACE MODIFICATION OF MICROPOROUS HOLLOW FIBER 
MEMBRANES 
2.1 INTRODUCTION 
In vivo, the endothelial lining of blood vessels presents an anti-thrombotic surface to circulating 
platelets and leukocytes [121]. The biohybrid lung discussed herein aims to replicate this surface 
on MHFs to promote biocompatibility of the device and potentially reduce anticoagulation 
requirements. As discussed in section 1.5.1, ECs expressing a non-inflammatory phenotype are 
capable of regulating hemostasis by expressing and/or secreting thrombomodulin, prostacyclin, 
nitric oxide, ectonucleotidases, tissue factor pathway inhibitor, heparin sulfate and type I 
plasminogen activator inhibitor.  
In order to achieve endothelialization of MHFs, surface modification was performed to 
promote cellular attachment. Surface treatment and endothelialization of MHFs is desirable since 
it creates a barrier to plasma weeping into the MHF pores. MHFs are inherently non-conducive 
to cell adhesion; therefore several surface modifications were evaluated to determine the 
appropriate treatment to encourage EC attachment. Additional criteria included maintaining ECs 
in culture, and obtaining near-confluent EC coverage with minimal incubation periods.  
 Proteins commonly found in the extracellular matrix secreted by ECs, particularly that of 
the arterial wall, were considered to promote EC attachment. This lists includes collagen, 
fibronectin, laminin and elastin [88, 122]. Specifically collagen, gelatin and fibronectin were 
evaluated as potential surface modification proteins for the biohybrid lung prototype. Gelatin 
was chosen since it is less thrombogenic in comparison to collagen, but provides the desirable 
adhesive properties associated with collagen. Fibronectin was selected since it has shown an 
ability to encourage EC growth and proliferation [88].  
 29 
 Initial cell adhesion and viability tests were performed with HUVECs on PP, siloxane 
coated polypropylene fibers (polydimethyl-siloxane PDMS) and PMP fibers. As the biohybrid 
lung prototype evolved, it was found to be advantageous to use BAECs so that blood-surface 
biocompatibility testing could be performed with bovine blood. Polymethylpentene fibers were 
selected as the appropriate MHF for the biohybrid lung due to their asymmetric porosity design, 
which limits plasma leakage in comparison to polypropylene fibers, and ready availability in 
comparison to siloxane-coated polypropylene fibers. Therefore, methods and results will be 
separated into HUVEC and BAEC sections to avoid confusion.  
2.2 METHODS 
2.2.1 Surface modification of MHFs to support HUVEC growth 
MHF mats of PP fibers (Celgard Inc., Charlotte, NC), PDMS (Senko, Japan), or PMP 
(Oxyplus/Membrana, Celgard Inc., Charlotte, NC), were cut into patches of 30 fibers, measuring 
2.5 cm in length. Six MHF patches were glued (60% Polycin, 40% Vorite by mass, 2 part 
polyurethane adhesive, Cas Chem, Bayonne, NJ) into a 50 ml conical tube, in an alternated 
pattern, per surface modification. One drop of glue was applied to both edges of the MHF patch. 
One tube was left unmodified to serve as a control.  
Select groups of fiber patches underwent radio frequency glow discharge (RFGD) (Super 
Plasmod, March Plasma, Concord, CA), while glued into a 50 ml conical tube, with the cap 
removed. The pressure in the RFGD chamber reduced to 0.3 Torr. Ammonium gas was pulled 
under vacuum into the energized chamber (current of 100 Watts) for 60 seconds.  
Following optional RFGD treatment, all fiber groups were sterilized with ethylene oxide 
gas (ETO) at 48°C (EO Gas™). Protein adsorption was applied following ETO sterilization. 
Select groups received additional surface treatment with coatings of fibronectin (Sigma, St. 
Louis, MO), type-I collagen (Sigma), Matrigel (BD Biosciences), BDI (Sigma), and BDI with 
RGDS (Sigma). Fibronectin was applied at 5 μg/mL. Collagen and Matrigel were applied to 
fully coat samples in a 6-well plate with a dilution of 1:5 (matrigel: PBS or collagen:PBS). 
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Protein adsorption with fibronectin, collagen or matrigel was performed in an incubator at 37ºC 
and 5% CO2 for 45 minutes to 1 hour. BDI was applied, as provided by the manufacturer, in 
enough volume (0.5 mL) to cover the sample for 10 minutes, with minimal air contact to the 
BDI. RGDS was applied as a solvent at a concentration of 100 μg/mL. Some samples received 
the surface treatment following RFGD pre-treatment, while other samples did not receive 
treatment or only received RFGD treatment.  
After surface modification, HUVECs (Cambrex, CC-2519) were added to 50 mL conical 
tubes to give a total cell seeding density of roughly 4 x 105 cells. The tubes were placed on a 
hematology mixer (one set speed) overnight in an incubator at 37ºC and 5% CO2. The following 
day, seeded patches were removed and placed into a static culture environment in six-well plates. 
HUVECs were cultured in endothelial growth medium (EGM™-2MV-Microvascular EC 
Medium-2, Cambrex, CC-3202) in an incubator at 37°C with 5% CO2.  
Mitochondrial activity was measured by the methylthiazolyl diphenyl-tetrazolium (MTT) 
(Sigma, M 5655) assay at days 1, 4 and 7. MTT is water soluble tetrazolium salt that can be 
converted to an insoluble purple formazan by cleavage of the tetrazolium ring by dehydrogenase 
enzymes, such as active mitochondrial dehydrogenases of living cells [123]. This conversion will 
not occur with dead cells. The insoluble formazan is solubilized with isopropanol, and measured 
spectrophotometrically at a wavelength of 570 nm to obtain an absorbance [123]. MTT was 
diluted with PBS (1:10) and added at a concentration of 5 μg/mL to cell culture medium on 
endothelialized MHFs. After a 3-5 hour incubation period, endothelialized MHFs were 
transferred to a new 6-well plate, where a 0.04 M HCl/isopropanol solution was added to replace 
the original volume of cell culture medium. Absorbency measurements were read the following 
day. MTT calibration curves were made by plotting the cell number (x-axis) against the 
absorbency corresponding to the cell number (y-axis). 
Cellular adhesion is expressed as either absorbance or cells/cm2. Data expressed as 
absorbance do not have relative calibration curves, so the data cannot be converted to cells/cm2 
or % cell coverage. Data for polypropylene fibers are shown in shades of green, data for PDMS 
fibers are shown in shades of blue, and data for PMP fibers are shown in shades of purple.  
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2.2.2 Surface modification of PMP MHFs to support BAEC growth 
Mats of PMP MHFs (a gift from Celgard) were cut into patches of 30 fibers, measuring 2.5 cm in 
length. Six MHF patches were glued (60% Polycin, 40% Vorite by mass, 2 part polyurethane 
adhesive, Cas Chem) into a 50 mL conical tube per surface modification. One tube was left 
unmodified to serve as a control. Select groups of fiber patches received RFGD (March Plasma 
Systems) treatment as described in section 1.2.1. The MHF surface became more hydrophilic, as 
verified by a decrease in the water in air contact angle.  
All fiber groups were sterilized with ETO gas at 48°C (Cellomics, EO Gas™). Select 
groups received additional surface treatment with type I collagen (Sigma, C9791), gelatin 
(Sigma, G1393) or fibronectin (Sigma, F1141). Type I collagen was applied at 10 μg/mL, gelatin 
was applied at 0.2% (1 μL/cm2, as provided by the manufacturer) and fibronectin was applied at 
5 μg/mL.  
Bovine aortic ECs (BAECs) (Cambrex, BW-6002) were cultured in endothelial growth 
medium (EGM™MV-Microvascular EC Medium, Cambrex, CC-3125) in an incubator at 37°C 
with 5% CO2 until confluence before being seeded onto MHFs. After surface modification, 
BAECs were added to 50 mL conical tubes to give a total cell seeding density of approximately 
4 x 105 cells. The tubes were placed on a hematology mixer overnight. The following day, 
seeded patches were removed and placed in six-well plates for a period of static culture. 
Mitochondrial activity was measured by the MTT assay at days 1, 2, 3, 5 and 7. Cellular 
adhesion is expressed as % cell coverage, based on absorbency readings. Refer to Appendix B 
for % cell coverage calculations. 
2.2.3 Statistics for MHFs to support HUVEC growth 
Results are displayed as ± standard deviation (± SE). Repeated measures ANOVA testing was 
used to compare HUVEC coverage. Post-hoc Newman Keul tests were used to compare surface 
modification data at selected time points, or to compare selected time points for specific surface 
modifications. Significance was considered to exist at p<0.05. 
 32 
2.2.4 Statistics for PMP MHFs to support BAEC growth 
Results are displayed as ± standard error of the mean (± SE). Repeated measures ANOVA 
testing was used to compare BAEC coverage. Post-hoc Newman Keul tests were used to 
compare surface modification data at each time point, and comparison of time points for specific 
surface modifications. Significance was considered to exist if p < 0.05. 
2.3 RESULTS 
2.3.1 Surface modification of MHFs to support HUVEC growth 
RFGD with ammonium gas was implemented to provide attachment of amine groups to the 
surface of the polymer. MHF samples modified with RFGD were evaluated with x-ray 
photoelectron spectroscopy (XPS, at NESAC/BIO, University of Washington) to quantify amine 
attachment. Nitrogen groups were not detected on these samples, and therefore amine attachment 
was shown to be unsuccessful. However, the MHF surface did become more hydrophilic, as 
verified by contact angle on polypropylene films treated with RFGD. The hydrophilic RFGD 
modification did promote EC attachment, as shown below. 
A combination of RFGD and fibronectin treatment provided a statistically significant 
increase (p<0.05) in mitochondrial activity attributed to HUVEC fiber coverage by day 7, as 
compared to untreated, RFGD treated or fibronectin treated MHFs. This occurred on both 
polypropylene and PDMS MHFs and is shown in Figure 2-1. 
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Figure 2-1 Fibronectin effect on HUVEC growth on PP and PDMS MHFs 
Comparison of EC growth on polypropylene and PDMS fibers treated with RFGD, fibronectin, or a 
combination. At day 7 RFGD and fibronectin treated MHFs had significantly (p<0.05) more HUVEC 
activity than all other surface treatment groups, for both polypropylene and PDMS fibers (n=6). 
 
 There was no statistically significant difference by day 7 of HUVEC growth on PDMS 
fibers that were collagen coated, matrigel coated, RFGD modified, or RFGD modified with 
collagen adsorption, shown in Figure 2-2. 
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Figure 2-2 Collagen and matrigel effect on HUVEC growth on PDMS MHFs 
Comparison of HUVEC growth on PDMS fibers treated with RFGD, collagen, collagen with RFGD, 
matrigel coatings, and a control (n varies from 2 to 6) 
 
Figure 2-3 shows HUVEC growth on PDMS fibers treated with RFGD alone, BDI alone, RFGD 
and BDI, BDI and RGDS, or RFGD with BDI and RGDS. At day 7 of HUVEC growth there 
were no statistically significant differences between the more important surface treatment groups 
of RFGD, RFGD with BDI, or RFGD with BDI and RGDS. Morphological changes were 
observed on PDMS fibers treated with BDI. The fibers appeared to reduce in size and become 
more brittle.  
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Figure 2-3 RGDS effect on HUVEC growth on PDMS MHFs 
Comparison of EC growth on PDMS control fibers and PDMS fibers treated with RFGD or RFGD, BDI 
and RGDS (n=5) 
 
2.3.2 Surface modification of PMP MHFs to support BAEC growth 
To encourage BAEC attachment, various surface modification techniques were investigated. 
Evaluated surface types consisted of control PMP MHFs, PMP MHFs modified with RFGD and 
PMP MHFs modified with RFGD and protein adsorption (collagen, gelatin or fibronectin). 
BAEC coverage increased significantly with the RFGD treatment of PMP MHFs within the first 
day of culture (p<0.05). Coverage increased even more with protein adsorption. RFGD 
modification in combination with fibronectin adsorption resulted in the greatest amount of 
BAEC coverage onto MHF patches in the shortest period of time. By day 5 of culture PMP 
MHFs treated with RFGD and fibronectin had significantly more BAEC coverage than any other 
surface treatment (p<0.05). By day 7 of culture near BAEC confluence was achieved on PMP 
MHFs treated with RFGD and gelatin or Fn. This coverage was statistically greater in 
comparison to other surface treatments (p<0.05). Figure 2-4 shows difference in BAEC growth 
on five surface types.  
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Figure 2-4 BAEC coverage on PMP MHF patches of varying surface modification 
* indicates BAEC coverage was statistically significantly greater on PMP fibers treated with RFGD and 
fibronectin adsorption than all other groups at day 5 (p<0.05). ** indicates BAEC coverage was statistically 
significantly greater on PMP fibers treated with RFGD and fibronectin adsorption than all other groups 
except PMP fibers treated with RFGD and gelatin adsorption at day 7 (p<0.05). Error bars represent SEM. 
2.4 DISCUSSION 
With modification of MHF patches, EC attachment and confluent coverage was obtained for 
both HUVECs and BAECs. Surface modification with RFGD followed by fibronectin adsorption 
consistently showed favorable cell attachment and proliferation results on all three fiber types 
(PP, PDMS, PMP). The BDI and RGDS treatment was eliminated, due to morphological changes 
of the fibers attributed to the BDI. Full endothelialization of MHFs was quickly obtained with 
treatment of RFGD followed by either gelatin adsorption or fibronectin adsorption in studies 
utilizing BAECs. These surface treatments provide effective ways to quickly enhance cell 
attachment and growth on MHFs, and have been shown to heighten cell retention [81] [72, 82]. 
Takagi et al. showed increased cell attachment on PP MHFs with adsorbed or covalently bonded 
Untreated
RFGD
RFGD + Collagen
RFGD + Gelatin
RFGD + Fibronectin
*
**
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pronectin, gelatin and fibronectin, compared to control, unmodified PP MHFs. EC coverage was 
greatest on PP MHFs treated with fibronectin [72].  
BAECs also grew well on MHFs treated with RFGD and collagen, however this may not 
be an ideal surface treatment since collagen is a pro-thrombotic protein. Thrombotic deposition 
might be more likely to form on a collagen coated surface if full endothelialization were not 
achieved. Therefore, it is imperative to select a surface modification that will maintain an anti-
thrombotic surface for the biohybrid lung prototype. Work has been done by others to combat 
thrombotic deposition by modifying MHFs with coatings of heparin or siloxane. Such modified 
fibers reduce plasma filling of the micropores by presenting a thin coating, however gas 
diffusion is limited by the coating [124].  
PMP fibers are desirable for deterrence of plasma leaking due to a non-symmetric design 
that consists of non-uniform porosity which is higher at the inner fiber lumen. RFGD treatment 
of MHFs showed an increase in hydrophilicity on the fiber surface that could promote protein 
adsorption at the open pore meniscus, the gas-blood interface of PP fibers. PMP fibers already 
present a thin skin to inhibit plasma leakage, so increased hydrophilicity is less of a concern in 
respect to plasma leakage for these fibers. ECs prefer to attach to hydrophilic surfaces, making 
the RFGD treatment favorable for PMP fibers.  
ECs also preferred to attach to the nylon weft fibers of MHFs. ECs would adhere and 
initially grow on wefts in larger numbers than on the actual MHF surface. MHFs without surface 
treatment had highest EC coverage on the wefts with little coverage on the MHF. Wefts may 
present a more thrombogenic surface than the MHF, therefore confluent EC coverage of this area 
may be desirable.  
EC growth and coverage were followed over a 7 day period to more accurately compare 
surface modifications using low initial seeding densities. If higher cell seeding densities were 
used, EC confluence could be achieved on PMP MHFs modified with RFGD and gelatin 
adsorption, or RFGD and fibronectin adsorption, in 1 to 2 days. This information is relevant to 
obtain EC coverage more rapidly, but it was also valuable to distinguish which surface treatment 
would encourage more EC growth over a longer period of time. If a less than desirable quantity 
of cells is available for use in the biohybrid lung, figure 2-4 shows that higher cell coverage will 
be obtained with RFGD surface modification and fibronectin adsorption for MHFs in less time 
than with the other surface modifications shown.   
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3.0  BIOREACTOR DEVELOPMENT 
3.1 INTRODUCTION 
The biohybrid lung provides a system to study EC phenotype and shear response. It also 
incorporates oxygenation into an active mixing device with a biological component, ECs. 
Material components selected for use in the biohybrid lung prototype were evaluated for their 
potential cytotoxicity and overall impact on device performance. Careful thought was given to 
the design of separate gas and liquid pathways within the device. A bearing and seal 
configuration was selected to facilitate active mixing within the device through the use of a 
rotating center piece. The center piece has a shaft that fits into the bearing and seal housing. The 
nature of this design can be very demanding on torque requirements from the motor. High torque 
requires careful seal selection for the intended application. When the constraints of a 37°C, high 
humidity, high salinity environment are included, along with extended use of up to 7 days, and 
rotational speed of 1500 RPM, seal selection becomes even more crucial. Seals can degrade, 
which can cause leaking and formation of debris. Heat generation is also a common complication 
associated with rotating seal/bearing designs. 
Multiple factors were taken into consideration for design of the biohybrid lung prototype. 
In addition to cell cytotoxicity, active mixing, and oxygen delivery, the biohybrid lung prototype 
was designed to minimize the use of expensive resources such as cell culture medium and blood, 
as well as maintain sterility. This chapter will discuss the development of a biohybrid lung 
prototype used to facilitate active mixing of endothelialized MHFs in cell culture medium or 
blood at rotational speeds of up to 1500 RPM.  
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3.2 METHODS 
3.2.1 Biohybrid lung prototype design and development  
The main design objectives of the biohybrid lung prototype specified that oxygen flow through 
the lumens of the MHF bundle under rotation, sterility be maintained and components be able to 
withstand elevated levels of humidity and temperatures of 37°C for the duration of each 
experiment. Bioreactor components must be able to undergo sterilization and remain sterile upon 
device assembly. In addition, fluid transfer should be conducted with ease. Medium may be 
changed with disposable syringes through luer ports, or it may be circulated with a perfusion 
system. Either way, it is important that rotation of the MHF bundle not be stopped during an 
experiment.  
Oxygen and carbon dioxide probes were used to access medium. Final raw materials 
consisted of cast acrylic for the housing, Teflon for removable housing caps, titanium shafts 
treated with diamond-like carbon coating (Anatech LTD), titanium screws and a titanium module 
base. Bioreactor parts, including titanium, end caps and housing, were machined by Daniel T. 
McKeel at the McGowan Institute for Regenerative Medicine. Shafts were initially made from 
medical grade stainless steel (316L), but this lead to corrosion and pitting. Bearings were 
stainless steel. The final seals were Teflon (ES Dygert Co.). Earlier seals were made from nitril 
or vyton (Chicago Rawhide, 711803 & 721526), but leaking and debris resulted. A continuous 
duty servo-brushless motor and power supply (Parker Hannifin Corp.) with the ability to vary 
speeds in small increments from 1 RPM to greater than 1500 RPM was selected. The controller 
interface was located outside of the incubator. A schematic of the final version of the biohybrid 
lung incorporating the desired characteristics is shown below (Figure 3-1).  
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Figure 3-1 Schematic of biohybrid lung prototype 
 
In order to best determine materials appropriate for use in the biohybrid lung prototype, 
components were tested individually and as a unit. Individual components such as stainless steel, 
titanium, nitril seals, vyton seals, and Teflon seals were soaked in EGM-MV medium for up to 7 
days. The medium and components were viewed under the microscope for signs of debris, 
degradation and corrosion. Cell viability was assayed for endothelialized wells that were 
incubated with materials from the biohybrid lung prototype versus a control of seeded wells, for 
up to 7 days. Alamar Blue (Biosource, cat# DAL1100), a non-destructive cell viability assay, or 
MTT (Sigma M 5655), a destructive cell viability assay was used [123, 125]. The MTT assay 
was described in section 2.2.1. Alamar Blue is soluble and non-toxic, therefore cell growth and 
proliferation can be monitored while the cells are in use. A dilution of 1:10 (Alamar Blue: cell 
culture medium) was applied directly to cell culture medium from the stock solution supplied by 
the manufacturer. Alamar Blue reduction was measured on a spectrofluorometer at 570 nm and 
600 nm, following 5 hours of incubation with ECs and bioreactor components. The percent 
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reduction of Alamar Blue was calculated and compared to a calibration curve to estimate the 
number of viable cells present in the sample [125, 126]. 
The complete system ran in water, medium and with HUVECs for several days. Visual 
assessment was applied to detect any accumulation or floating debris. Medium and components 
were microscopically evaluated for signs of corrosion and degradation.  
3.2.2 Bioreactor Sterility and Assembly 
Much attention was given to assembly of the device to maintain sterility. MHF bundles were 
sterilized with ETO gas before BAECs were seeded on to them. Seeding tubes were sterilized 
with ETO gas as well, to maintain sterility before the bundle was placed in the bioreactor. 
Bioreactor parts and assembly equipment was ETO gas sterilized prior to setup with sterile 
procedure in a cell culture hood. The following pieces were ETO gas sterilized for every 
bioreactor setup: vice, plastic guide tube (cut cast acrylic of ½” inner diameter), 2 open conical 
tubes of thread, tweezers, razors, thermocouple, silicone tubing, tubing connectors (luer locks, 
luer locks with barbs, etc.), bioreactor shaft guide (a custom made titanium cylinder of 3” length 
open on one end with an inner diameter of 3/8”), 8 strips of parafilm, bioreactor housing, 2 end 
caps, 2 screws to hold the MHF bundle, 2 titanium shafts, seals in holders, bearing in holders, 4 
custom made Teflon gaskets, 6 screws to hold the end caps, 1 rubber stopper, and one custom 
made air outflow gasket. Two sterile 3-way stopcocks and one T-75 tissue culture flask cap were 
also used during assembly. 
All sterile pieces were laid out on open sterile ETO packages for assembly. The 
endothelialized MHF bundle was taken from the seeding tube with tweezers and shafts were 
screwed into the ends. Thread was wrapped, with the aid of the mini-vice and plastic tube, 
around balloon seals covering the shafts to separate the gas and liquid pathways. The shaft guide 
was used for assembly of the MHF bundle into the distal end seal and bearing holders. An outer 
layer of MHFs was cut off of the MHF bundle. This layer served as a protective barrier during 
cell seeding, cell growth and initial device assembly. It was originally wrapped on top of balloon 
seals covering the MHF bundle. The MHF bundle was then inserted into the bioreactor housing 
and the proximal end seals and bearings were secured into place with assistance of the shaft 
guide. Silicone tubing and stopcocks were attached to the medium sampling ports. 50 mL of cell 
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culture medium was added to the device. The thermocouple was inserted through the rubber 
stopper and placed in one of the two probe holder positions. The tissue culture flask cap was 
placed on top of the other probe holder. Both were secured with parafilm. Following assembly, 
the bioreactor was immediately placed in the incubator. 
 
3.2.3 Shear Stress Calculations for Rotation of a MHF Bundle 
The Navier-Stokes motion equations for rotation of an inner cylinder in a stationary cylinder 
were applied for constant ρ (density) and μ (dynamic viscosity). The governing equation is given 
below (Equation 7) [127]. 
 
Equation 7 Navier-Stokes equation for cylindrical coordinates (r-component), constant ρ and μ 
 
 
 The equation was evaluated in one-dimension, in the theta direction with respect to r. The 
following assumptions were made. Fluid flow is in the θ-direction (Equation 8).  
 
Equation 8 Fluid flow in ө-direction 
vө ≠ 0, vr = 0 
 
Fluid velocity is only a function of r (Equation 9). 
 
Equation 9 Fluid velocity is only a function of r 
vө = f(r) 
 
Gravity and pressure effects are negligible (Equation 10). 
 
Equation 10 Gravity and pressure effects are negligible 
gө = 0, p=p(r,z)=0 
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Fluid flow is assumed to be at steady state (Equation 11). 
 
Equation 11 Steady State Flow 
0=∂
∂
t
 
 
The Navier-Stokes equation was simplified with the above assumptions (Equation 12). 
 
Equation 12 Simplified Navier-Stokes equation 
( )⎟⎠
⎞⎜⎝
⎛= θrv
dr
d
rdr
d 10  
 
Equation 12 was solved to obtain vө (Equation 13). 
 
Equation 13 Equation for vө
vө = C1r/2 + C2/r 
 
Boundary conditions were chosen (Equation 14) 
 
Equation 14 Boundary conditions 
@ r = Ri, vө = ΩRi
@ r = Ro, vө = 0 
 
The boundary condition for a given radius is r. Ri is the radius of the titanium module with 
MHFs and Ro is the radius of the inner wall of the bioreactor housing. Ω is the angular velocity. 
The equation for vө with the given boundary conditions substituted in is shown (Equation 15). 
 
Equation 15 Boundary conditions substituted into the equation for velocity in the ө direction 
( ) ( )22 2222 2 io oiio i RRr RRRR Rrv −Ω+−Ω−=θ  
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The angular velocity, Ω, is found from RPM multiplied by circumference. The dynamic viscosity 
is given as μ. The shear rate is given below with units of [s-1] (Equation 16). 
 
Equation 16 Shear rate 
( )( )222
222
io
oi
RRr
RrR
dr
dv
−
+Ω=−= θμ
τ  
 
The shear stress, with units of [dynes/cm2], is found by multiplying the shear rate with the 
dynamic viscosity (times a factor of 10 for unit conversion). The dynamic viscosity of blood is 3 
cp, or 0.003 Ns/m2. 
3.3 RESULTS 
3.3.1 Biohybrid lung prototype design and development  
The first biohybrid lung prototype is shown below with the addition of Alamar Blue in the cell 
culture medium (Figure 3-2). 
 
 
Figure 3-2 Original biohybrid lung prototype 
 
 Alamar Blue was originally used to assess live cell number within the device, and is 
shown in Figure 3-2. However, control experiments showed that Alamar Blue was not accurate 
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in predicting cell number above 4 x 105 to 5 x 105 cells. Original materials of stainless steel 316L 
resulted in corrosion and pitting, and debris formation by the vyton (or nitril, not shown) seals, as 
shown (Figure 3-3 & Figure 3-4). 
 
 
Figure 3-3 Original biohybrid lung prototype stainless steel components 
Corrosion and pitting occurred with original stainless steel bearings and shafts 
 
 
Figure 3-4 Vyton seal exhibited debris in the original biohybrid lung prototype 
 
The final prototype of the biohybrid lung is shown below (Figure 3-4).  
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Figure 3-5 Finalized biohybrid lung prototype 
 
An exchangeable MHF bundle and seeding tube are shown below (Figure 3-6). The 
inner, outer and middle fiber layers are exposed when looking down the cylinder. 
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 21 mm 
Figure 3-6 Microporous hollow fiber bundle and seeding tube 
Microporous hollow fiber matt potted around a titanium core: (a) side view, (b) looking down the core, (c) 
custom made seeding tube with a permeable membrane end cap. 
 
The prototype allows for gas flow through the lumen of MHFs during rotation through an entry 
and exit pathway. Rotation was increased gradually up to a tested speed of 1500 RPM. Custom 
made Teflon seals supported high levels of torque required for steady rotation of the MHF 
bundle. DLC coating on the titanium shafts provided a smoother finish that reduced friction 
between the shaft and bearing. However, as speed increased within the biohybrid lung prototype, 
heat production also increased. To compensate for heat generation, the incubator temperature 
was dropped incrementally with speed increases to an end temperature of 32°C. At speeds of 100 
RPM or greater a fan was positioned along the housing of the biohybrid lung prototype to 
dissipate heat. At speeds of 500 RPM or greater, room temperature air was directed onto the 
exterior of the biohybrid lung prototype housing.  
The system allowed for media exchange during continuous rotation. Oxygen and carbon 
dioxide levels could be monitored within the medium in the system through two separate ports. 
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Temperature was monitored with the addition of a thermocouple. BAECs remained viable under 
rotation in the biohybrid lung prototype throughout the testing period of 7 days or greater. 
3.3.2 Shear Stress Calculations 
After simplifying the Navier-Stokes equation, shear rates and shear stresses were calculated for 
the given RPM (Table 3). 
 
Table 3 Shear stress calculations 
RPM Wall Shear Rate (s-1) Wall Shear Stress (dynes/cm2) 
50 32.93 1.0
100 65.87 2.0
150 98.81 3.0
200 131.75 4.0
250 164.68 4.9
300 197.62 5.9
350 230.56 6.9
400 263.49 7.9
450 296.43 8.9
500 329.37 9.9
550 362.30 10.9
600 395.24 11.9
650 428.18 12.8
700 461.11 13.8
750 494.05 14.8
800 526.99 15.8
850 559.92 16.8
900 592.86 17.8
950 625.80 18.8
1000 658.73 19.8
1050 691.67 20.8
1100 724.61 21.7
1150 757.54 22.7
1200 790.48 23.7
1250 823.42 24.7
1300 856.35 25.7
1350 889.29 26.7
1400 922.23 27.7
1450 955.16 28.7
1500 988.10 29.6
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3.4 DISCUSSION 
A biohybrid lung prototype was successfully designed and constructed to rotate endothelialized 
MHF bundles. The final prototype was an evolution of several different prototypes to promote 
cellular retention. The final prototype differed from earlier prototypes by the use of titanium 
instead of medical grade stainless steel, and custom made Teflon seals instead of commercially 
available nitril and vyton seals. Inclusion of a servo-brushless motor was also crucial for 
achieving torque requirements. It was necessary to include cooling mechanisms, such as fans, 
lowered incubator temperature and a stream of room air, to maintain a physiologic temperature 
range. Experiments were easily lost to overheating or under heating without the use of a 
thermocouple and constant adjustment to cooling mechanisms. There were four copies of the 
prototype available for use. Two of the four units produced more heat generation than the others, 
even though they were “identical”. Heat production would also vary from experiment to 
experiment. Heat generation is common with rotating devices that have a shaft contacting 
bearings and seals. Bearings purged with a cooling fluid are sometimes implemented to address 
this problem. Many new rotational medical devices are switching to magnetically levitated 
impellers to reduce heat generation. However, with the biohybrid lung it was very difficult to 
implement such technologies due to the necessity of separating gas and liquid pathways.  
The final biohybrid lung prototype was EC compatible at speeds accelerated up to 1500 
RPM over a test period of 7 days or greater. Key features of this design included exchangeable 
MHF bundles, controlled rotation of MHF bundles, separation of the gas-liquid interface within 
the prototype, and ability to sample and exchange medium. It was critical to design a device that 
would not negatively impact cell retention so that EC response to shear stress and/or hyperoxia 
could be evaluated without confounding variables associated with device performance. 
Developing methods to maintain sterility within the device was also a major challenge. This was 
also a crucial aspect of the project due to the length of individual experiments. From the time 
BAECs were seeded onto the MHF bundle, to the time endothelialized MHF bundles were 
assembled into the biohybrid lung, to the time that the biohybrid lung experiment was 
terminated, approximately 3 weeks had passed. In those 3 weeks, numerous opportunities for 
contamination arose. Medium was changed daily, which required removal of the MHF bundle 
from the seeding tube during the first 1.5-2 weeks. A 20 minute assembly process was 
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implemented for bioreactor setup in the cell culture hood. Medium was exchanged via syringes 
through medium ports in the incubator. These ports were briefly open to air during medium 
exchanges. This technique of medium exchange was actually much more successful for avoiding 
contamination than medium exchanges through a perfusion system. When perfusion systems 
were implemented, they remained closed to air at all times. However, the abundance of surface 
area from tubing and connectors were likely factors leading to much more frequent device 
contamination.  
Separation of the gas-liquid pathway presented a design challenge for sterile, efficient 
assembly. If the device was not assembled, filled with cell culture medium and placed within the 
incubator within approximately 30 minutes, BAECs would die and the experiment would be lost. 
Initially, o-rings were intended to slip over the titanium shaft and balloon to seal and separate the 
gas-liquid pathway. An adequate seal could not be obtained with o-rings. Ultimately sterile 
thread was wrapped tightly around the balloon seals with sterile technique. This added additional 
time and complexity to the assembly process, but provided adequate separation of the gas-liquid 
pathway. 
The biohybrid lung prototype provides an ideal controlled system for studying ECs 
exposed to shear stress on MHFs. Sterility is maintainable within the system. With proper 
material selection it was shown that BAEC viability was also maintained. This prototype was 
designed to efficiently test EC function under shear stress in vitro. Maximum shear stresses were 
calculated for rotation rates up to 1500 RPM, which corresponded to a shear stress of 29.6 
dynes/cm2. Shear stresses were estimated for the outer fiber of the 3 layer fiber bundle. Middle 
and inner fiber layers would experience lower shear stresses, since they are protected by the 
outer fiber layer.  Shear stresses calculated for the biohybrid lung fall within the physiologic 
range. 
Shear stresses on ECs and MHFs may be higher than predicted using the Navier-Stokes 
equations. Taylor vortices have been reported to form in the gap between two concentric 
cylinders when the inner cylinder is rotated [128, 129]. Batten et al. have reported Taylor 
vortices at Reynolds numbers of 5x103 3 and 8x10  based on the gap width between two cylinders 
[128]. Refer to Appendix D for estimated Taylor numbers in the biohybrid lung prototype. High 
Taylor numbers are an indication of turbulent flow and higher fluid velocities around the MHFs 
and ECs, which may require that ECs form stronger adhesions to the MHFs and flatten more to 
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distribute more surface area. The function of adherent ECs may also change in response to 
Taylor vortices. A higher fluid velocity scheme may improve oxygen accumulation in the 
biohybrid lung by reducing boundary layer effects. 
Limitations still exist in the final biohybrid lung prototype, described herein. The system 
requires nearly continuous user attention to maintain a temperature of 37 ± 2ºC and viable cell 
culture medium. There are numerous variables that can lead to contamination of the system, or 
complete cell loss. The device has not been entirely optimized to promote blood-surface 
biocompatibility. A large portion of the blood contacting part of the device is composed of 
materials other than endothelialized MHFs. This includes the cast acrylic housing, Teflon seals, 
string, balloon seals between the gas and liquid pathways, end caps and fluid ports.   
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4.0  ENDOTHELIALIZATION AND ROTATION OF MHF BUNDLES 
4.1 INTRODUCTION 
Mixing within the biohybrid lung may reduce gas diffusion losses from blood boundary layers 
near individual MHFs. As discussed in section 1.4.3, active mixing in some devices, such as the 
PRAL, can increase gas transfer. However, little is known about the consequences of shear stress 
on ECs under rotational mixing. It is hypothesized that ECs in the biohybrid lung will be able to 
sustain physiologic rates of shear stress without detaching from the MHFs. In order to achieve 
endothelialization of MHFs, surface modification was performed to promote cellular attachment 
on MHF bundles. Surface treatment and endothelialization of MHFs creates a barrier to reduce 
plasma leakage, but in turn may limit gas diffusion.  
This chapter will discuss behavior and functionality of ECs observed within the biohybrid 
lung prototype. The biohybrid lung provides a system to study EC phenotype and shear response. 
BAECs were selected so that subsequent biocompatibility studies could be conducted with 
bovine blood. BAEC phenotype was evaluated with an antibody against p-selectin to quantify 
cellular expression of this inflammatory marker. Retention of BAECs on MHFs under rotation 
and expression of a non-inflammatory phenotype for BAECs exposed to shear stress under 
rotation are demonstrated. 
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4.2 METHODS 
4.2.1 Endothelialization of MHF bundles 
MHF mats were wrapped in three layers around a titanium core and potted to form a bundle 
(Figure 3-6). MHF bundles were surface modified by RFGD treatment. Following ETO gas 
sterilization, fibronectin adsorption was applied at 10 μg/mL and bundles were seeded with 
BAECs at a seeding density of approximately 15 x 106 cells. Cast acrylic seeding tubes were 
developed with a threaded removable cap outfitted with a permeable fluoro-ethylene based 
polymer membrane (Kimberly-Clark, self-seal plus sterilization pouch) to allow for improved 
gas transfer (Figure 3-6). Seeding tubes containing BAECs and MHF bundles were placed on a 
hematology mixer and rotated for 12-24 hours in an incubator at 37°C at 5% CO2 before being 
placed in static culture. Near confluent cell growth was achieved within one to two weeks of 
seeding. Daily media exchange was performed. 
4.2.2 Rotation of endothelialized MHF bundles 
Following static culture, endothelialized modified MHF bundles were transferred with sterile 
techniques to the biohybrid lung prototype and left in static culture for several hours. Fiber 
bundle rotation began at 20 RPM and was increased in increments of 30-50 RPM every 2-3 
hours until the desired speed was reached. Media was exchanged daily through media ports of 
the system. Final speeds of rotation ranged from 250 RPM to 1500 RPM. Figure 4-1 illustrates 
RPM ramping to a speed of 750 RPM over 7 days. 
 54 
0150
300
450
600
750
0 50 100
Time (hours)
Sp
ee
d 
(R
PM
)
150
 
Figure 4-1 Protocol for acceleration of an endothelialized MHF bundle in the biohybrid lung prototype  
 
After the target speed was achieved in the biohybrid lung prototype and maintained for ≥ 
12 hrs, speed was decelerated over 2 hours. After deceleration the biohybrid lung prototype was 
disassembled and the MHF bundle was removed. Half of the bundle was rinsed in PBS two times 
for two minutes, fixed in 2% paraformaldehyde and rinsed in PBS for two minutes. The MHFs 
were subsequently labeled with Rhodamine-Phalloidin (Molecular Probes, R415) and DRAQ5 
(Biostatus Limited) for confocal imaging of BAEC F-actin filaments and nucleis, respectively. 
The other half of the bundle was treated with HEPES buffered saline solution, trypsin/EDTA and 
trypsin neutralizing solution to remove BAECs from the MHFs. BAECs were centrifuged at 220 
x g for 5 minutes and resuspended in PBS with calcium and magnesium to produce two 0.5 mL 
samples. One sample was incubated in the dark for 20 minutes with 5 μL of 0.1 mg/100µL of a 
monoclonal antibody against human P-selectin (Takara Mirus Bio, Madison, WI). The other 
sample was incubated in the dark for 20 minutes with 100 μL of mouse IgG1 isotype control 
monoclonal antibody (Caltag Laboratories, MG115). Both samples were centrifuged at 220 x g 
for 5 minutes. Samples were incubated with 20 µL of 1.5 mg/mL antimouse IgG(H+L)(cross-
adsorbed against bovine, human and equine serum proteins) goat FITC in the dark for 20 minutes 
(Pierce Biotechnology Inc, Rockford, IL). Samples were then centrifuged at 220 x g for 5 
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minutes. Samples were resuspended in 2% paraformaldehyde and evaluated with flow 
cytometry. A Becton-Dickinson FACScan was used to quantify percent of cells positive for 
binding of the antibody against p-selectin to the isotype control.  
4.3 RESULTS 
4.3.1 Endothelialization of MHF bundles 
BAEC confluence on MHF bundles was achieved within 1-2 weeks. Dynamic culture of 12-24 
hours, followed by static culture, was required for cell adherence and growth. Confluence could 
not be achieved without a static period of culture. The permeable membrane of the seeding tube 
supported adequate oxygenation during static culture. Without this membrane incorporated into 
the seeding tube, BAECs died within a few days. BAEC coverage is shown on MHFs prior to 
rotation (Figure 4-2) using an MTT assay.  
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 380 μm 
Figure 4-2 Endothelialized microporous hollow fiber bundle, without rotation 
MHFs stained with MTT 
 
BAEC coverage is also shown with confocal imaging using fluorescent labeling with rhodamine-
phalloidin and DRAQ5 (Figure 4-3). 
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 a) 
b) 
c) 
Figure 4-3 Endothelialized microporous hollow fiber bundle without rotation 
MHFs are labeled with DRAQ5 and rhodamine-phalloidin: (a) inner fiber layer (b) middle fiber layer (c) 
outer fiber layer 
4.3.2 Rotation of endothelialized MHF bundles 
After near BAEC confluence was achieved in static culture, MHF bundles were placed in the 
biohybrid lung prototype. Methods were perfected to transfer endothelialized MHF bundles into 
the prototype under sterile conditions. Rotation began at 20 RPM several hours after assembly, 
and was increased to 40 RPM 2 hours later. Rotation was then increased in increments of 30-50 
RPM approximately every 2 hours, except over-night, until the desired RPM was achieved. This 
strategy resulted in BAEC adherence at physiologic shear rates tested up to 29.6 dynes/cm2, 
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which corresponded to a rotation at 1500 RPM. BAECs frequently aligned perpendicular to fluid 
flow. More parallel BAEC alignment occurred at 750 RPM than 250 RPM. 
The initial seeding strategy involved seeding cells directly into the bioreactor. HUVECs 
(used before the switch to BAECs for blood biocompatibility studies) were seeded onto MHF 
modules in the bioreactor and had shear stress continually applied with the intention of growing 
cells under shear stress. Immediately following cell deposition, the bioreactor was transferred to 
the incubator, attached to the motor and rotation began at 20 RPM. This approach did not result 
in cell attachment and retention. Cell viability was shown at day 1 in the bioreactor using Alamar 
Blue. Day 2 evaluation with Alamar Blue indicated a large reduction in viable cells. By day 3 no 
response was indicated via Alamar Blue. MTT staining and adsorption supported the conclusion. 
The majority of BAECs from MHF bundles had levels of inflammation slightly elevated 
from base line, post-rotation. In tissue culture flasks BAECs stimulated with IL-1β or TNF-α 
expressed 20% and 26% P-selectin, respectively. BAECs taken from MHF bundles routinely 
expressed 4-8% p-selectin. Isotype controls were set to 2% binding levels to account for non-
specific binding of IgG isotype antibodies and cell autofluorescence. However, similar elevated 
levels of P-selectin expression were found on MHF bundles prior to rotation. There was not a 
significant difference for p-selectin expression between BAECs from isotype control groups 
(sample size of 7) and BAECs from rotated MHF bundles (sample size of 7), but there was a 
significant difference between BAECs from rotated MHF bundles and positive control groups of 
BAECs stimulated with TNF-α or IL-1β (sample size of 4), when evaluated with one-way 
ANOVA with post-hoc comparison using Tukey’s test for significance of p<0.05.  
Uniform BAEC coverage was frequently found throughout the top, middle and bottom 
layers of MHF bundles at 250 RPM (Figure 4-4). 
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 b) 
a) 
c) 
Figure 4-4 Endothelialized microporous hollow fiber bundles with rotation 
MHFs are labeled with DRAQ5 and rhodamine-phalloidin, rotated at 250 RPM: (a) inner fiber layer (b) 
middle fiber layer (c) outer fiber layer 
 
 Preferred BAEC coverage on the outer MHF layer at speeds ranging from 500-1500 
RPM is shown below (Figure 4-5). Rhodamine-Phalloidin is shown in red and DRAQ5 is shown 
in blue. The degree of BAEC coverage did vary across the MHF bundle, but did not appear to be 
related to speed of bundle rotation. 
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Figure 4-5 Outer layer of endothelialized microporous hollow fiber bundles, with rotation 
MHFs are labeled with DRAQ5 and rhodamine-phalloidin: (a) 500 RPM (b) 750 RPM (c) 1000 RPM (d) 1500 RPM 
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4.4 DISCUSSION 
Near confluent BAEC coverage was obtained on MHF bundles modified by RFGD treatment 
and fibronectin adsorption, as seen with MHF patches. A key factor toward reaching confluence 
on the MHF bundles was not only the surface modification, but also the seeding technique. EC 
coverage could not be achieved when MHFs were seeded under continuous dynamic culture. 
MHF bundles seeded in seeding tubes and continuously rolled on a hematology mixer and MHF 
bundles seeded directly in the biohybrid lung prototype under rotation did not show any EC 
adherence after several days.  
The shear stress magnitude that BAECs may tolerate while maintaining a non-
inflammatory phenotype was examined in this biohybrid lung prototype. Near confluence was 
achieved at each shear stress tested, however dead cells consistently appeared in cell culture 
medium as it was replaced. BAECs appeared to flatten and spread out more at higher rotational 
speeds. BAECs did not appear to grow under rotational shear stress, as described earlier with 
observations made during the seeding process. Others have noted a quiescent state of 
endothelium, or lower proliferation of ECs in the presence of fluid flow exerting high shear 
stress [102, 107]. This may support the observation that near confluence was maintained while 
ECs were shed from the MHF bundles.  
In the biohybrid lung, cell alignment was observed in some instances, but the degree of 
alignment varied across the fiber surface. Alignment frequently appeared perpendicular to fluid 
flow, but sometimes alignment occurred in parallel to fluid flow. More parallel alignment was 
seen at 750 RPM than 250 RPM. However, fluid flow around MHFs is more complex than fluid 
flow in parallel plate experiments, and alignment may also be more complex. BAECs were 
observed to flatten and spread out with increased time and shear stress as well. Samet et al. 
reported that ECs seeded in a ventricle shaped perfusion chamber did not align with flow after 20 
hours of pulsatile flow at 1.5 dynes/cm2, but cell morphology did change [130]. Frame et al. 
found that flow-induced rearrangement of EC F-actin are dependent on the shape of the surface 
which ECs are grown on [131]. The shape of the underlying surface has more impact on EC 
response than the origin of the EC type, and may cause an altered response to flow. Significantly 
less EC alignment in the direction of laminar flow was observed for ECs grown on curved 
surfaces than ECs grown on flat surfaces, in the findings from Frame et al. [131]. 
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It has also been observed that laminar shear stress appears to protect ECs from 
inflammatory responses, by inhibiting tumor necrosis factor, and endothelial proliferation, and 
by inducing growth arrest proteins [99, 106]. Minimal levels of inflammation occurred with 
BAECs grown on MHF bundles whether or not these ECs were exposed to shear stress in the 
biohybrid lung prototype. Inflammation was evaluated using flow cytometric techniques to 
quantify expression of p-selectin. Ideally, other markers would be evaluated in combination with 
p-selectin. Antibodies against tissue factor, ICAM-1, e-selectin, VCAM-1 and PECAM-1 were 
evaluated with flow cytometric techniques for BAECs, but did not show upregulation in the 
presence of TNF-α or IL-1β in tissue culture flasks. However, some of these antibodies, 
antibodies against e-selectin, VCAM-1 and PECAM-1, did show expression using 
immunoflourescence and will be used to further evaluate BAEC phenotype. In addition, BAEC 
phenotype is evaluated further in subsequent chapters by exposing endothelialized MHFs to 
bovine blood to determine if thrombotic deposition is reduced in comparison to non-
endothelialized MHFs. A low level of inflammation may be tolerable if surface thrombogenicity 
is reduced related to a non-endothelialized MHF control.  
Rotation of endothelialized MHF bundles was evaluated up to 1500 RPM. EC near-
confluence was maintained at 1500 RPM. The shear rate for the outer layer of fibers in a MHF 
bundle rotating at 1500 RPM was calculated to be 29.6 dynes/cm2. More work is necessary to 
determine if mixing improves gas transfer within the biohybrid lung prototype, and to what 
extent. Fiber spacing and layout, as well as overall device design will most likely have a 
considerable influence on improving gas transfer. A device such as the Paracorporeal 
Respiratory Assist Lung (PRAL), developed by Federspiel et al. could be endothelialized and 
used to optimize gas transfer [64]. The PRAL has been designed to augment gas exchange by 
increasing fiber bundle rotation at a set fluid flow rate. Blood flow rate can be maintained at low 
levels and still provide clinically significant CO2 removal.   
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5.0  THROMBOTIC DEPOSITION AND INFLAMMATION IN THE BIOHBRID 
LUNG PROTOTYPE 
5.1 INTRODUCTION 
Artificial oxygenation in the intensive care setting is commonly conducted with two modalities, 
mechanical ventilation and ECMO. This type of support is often required for acute lung injuries, 
such as ARDS, chronic lung conditions, such as chronic obstructive pulmonary disease (COPD), 
and other conditions that may compromise pulmonary function [132].  For short-term 
applications, such as coronary bypass surgery, some concerns regarding blood oxygenator 
biocompatibility can be reduced with the use of heavy anticoagulation regimens [133]. When 
artificial oxygenation with blood oxygenators is required for extended periods of times, i.e. days 
instead of hours, issues concerning biocompatibility come to the forefront. In the case of 
mechanical ventilation, extended support cannot be maintained without the risk of mechanically 
induced tissue damage from high airway pressures, as well as biologically-induced tissue 
damage from hyperoxia [7, 8, 11-13]. In the case of ECMO, high levels of anticoagulation 
cannot be maintained without the serious risk of bleeding [40, 44].  
 The biohybrid lung prototype has been developed to address two of the primary blood 
biocompatibility issues associated with current ECMO systems. The oxygenators in ECMO units 
commonly use MHF bundles that are subject to plasma infiltration into the open pores of the 
fiber wall over time. This phenomenon, also referred to as plasma weeping, markedly reduces 
gas exchange rates [35]. In addition, platelets may adhere and become activated by the artificial 
surfaces of the oxygenator, particularly the high surface area of the MHFs [134-136]. Adherent 
platelets can become activated, form aggregates and support the blood coagulation cascade. To 
reduce the risk of thrombus formation, which can reduce gas transfer rates and lead to 
thromboembolism, high levels of heparin anticoagulation are required. High levels of 
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anticoagulation together with the depletion of platelets and coagulation factors due to surface 
activation lead to increased risk of bleeding and further complications [32]. 
 Endothelialization of the surfaces of MHFs is intended to present a more biocompatible 
surface, one that is actively anti-thrombotic. Ideally, circulating blood will interact with 
autologous ECs on MHFs as it would with autologous ECs lining blood vessels. This chapter 
investigates to what degree this may be true, at least acutely, using in vitro experiments with 
BAECs and bovine blood.  Issues of sub-confluent EC coverage, inflammation of ECs and 
different surface modifications are also addressed.   
 Blood-surface biocompatibility was evaluated by quantifying thrombotic deposition on 
MHF patches. These studies were used to compare surface modifications, non-endothelialized 
MHFs to endothelialized MHFs, and sub-confluent endothelialized MHFs to confluent 
endothelialized MHFs. From these data the optimal surface modification was selected and 
applied to MHF bundles for the biohybrid lung prototype. Thrombotic deposition and EC 
phenotype were then evaluated for MHF bundles rotated at target speeds of 250 RPM or 750 
RPM. This chapter explores the effect of endothelialization on biocompatibility in the biohybrid 
lung prototype. 
5.2 METHODS 
5.2.1 Bovine blood collection and preparation  
Blood was collected via jugular venipuncture of adult female Holsteins with an 18 gauge, 
1½” needle, and mixed into collection bags with 10% acid citrate dextrose (ACD) (10 mL of 
Solution A ACD to 90 mL of bovine blood). Collection bags were then transferred in coolers 
back to the University of Pittsburgh McGowan animal facility for re-calcification. Blood was 
first heparinized with 0.5 U/mL, then subsequently re-calcified with 1M CaCl2+ to a final 
concentration of 2-3 mM calcium and balanced to a pH of 7.4 with 1M NaOH on an ABL (blood 
gas analyzer) (700 series, Radiometer Copenhagen). All blood was used within 24 hours of 
collection and stored at 2-8°C prior to use. 
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Heparinization levels appropriate for comparison of different surface modified MHF 
patches were determined by a control experiment with non-modified MHF patches exposed to 
varying heparin concentrations ranging from 0.5-0.8 U/mL. Heparinized blood was warmed in 
an incubator at 37°C for 15 minutes prior to use. Patches were placed in 6 mL siliconized 
Vacutainer® tubes containing no additives (BD Biosciences) with 5 mL of heparinized blood. 
Tubes were placed on a hematology mixer (Medmark Technologies LLC.) in an incubator at 
37°C and 5% CO2 for 2 hours. Visual inspection of tubes was made at 30, 60, 90 and 120 
minutes. Two samples were evaluated at each heparinization level. Heparin concentrations 
desirable for experiments were determined based on the control, untreated MHFs exhibiting a 
level of thrombotic deposition that was visually apparent. A concentration of 0.6 U/mL heparin 
was commonly chosen.  
 
5.2.2 MHF patches exposed to bovine blood 
Once an appropriate level of anticoagulation was selected, surface modified, endothelialized 
MHF patches were evaluated. The heparin concentration was adjusted to the desired level, and 
blood was warmed for 15 minutes prior to use. 5 mL of blood was added to each Vacutainer® 
tube. One surface modified, endothelialized patch was placed in each tube and incubated on the 
hematology mixer for 2 hours. Following incubation, fiber patches were removed and placed in a 
heparin/saline rinse solution of 10 U/mL heparin. Images of thrombotic deposition were taken 
with a digital camera (Nikon Coolpix 4500) on a dissecting scope (Nikon SMZ660, 10x eyepiece 
magnification with a 0.6x objective, yielding 6x magnification). Twenty samples were tested for 
each surface modification technique at each time point, with the exception of a few samples lost 
during the experimental process for a variety of reasons. Total sample number was 493. Five 
independent blood collections were performed to test 100 samples per blood draw. 
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5.2.3 MHF bundles exposed to bovine blood 
Non-endothelialized, non-surface modified PMP MHF bundles were setup in the biohybrid lung 
prototype and spun at the target speed of 250 RPM or 750 RPM to serve as controls. 120 mL of 
heparinized bovine blood (0.8 U/mL heparin) was passed through the system through the 
medium perfusion ports, with 50 mL of the blood left in the biohybrid lung prototype for 2 hrs of 
incubation. For surface modified, endothelialized MHF bundles, heparinized bovine blood (0.8 
U/mL heparin) was introduced and incubated for 2 hrs after the target speed was achieved within 
the biohybrid lung prototype and maintained for ≥ 12 hrs.   
Following incubation, the biohybrid lung prototype was disassembled and the MHF 
bundle was removed. Control MHF bundles were cut in half for light microscopy imaging and 
SEM preparation. Endothelialized MHF bundles were cut in quarters for light microscopy 
imaging, SEM imaging, confocal imaging and flow cytometric evaluation. Bundle portions 
designated for light microscopy were rinsed and stored in 10 U/mL heparin/saline rinse solution. 
Bundle portions designated for SEM imaging were rinsed in 10 U/mL heparin rinse solution, 
rinsed in PBS, soaked in 2.5% glutaraldehyde at room temperature for one hour, rinsed in PBS 
three times and stored in PBS. Bundle portions designated for confocal imaging were rinsed in 
10 U/mL heparin rinse solution, rinsed in PBS, fixed in 2% paraformaldehyde and rinsed in PBS 
for two minutes. The MHFs were subsequently labeled with antibodies against PECAM-1 
(monoclonal mouse anti-ovine CD31, Serotec) or E-selectin (polyclonal CD62E/Endothelial 
Leukocyte Adhesion Molecule, Labvision) (dilution of 10 μL antibody to 500 mL PBS). 
Following primary antibody incubation, samples were incubated with secondary antibodies (4 μL 
per 500 mL PBS), Rhodamine-Phalloidin (dilution 2:1000, F-actin stain) (Molecular Probes, 
R415) and DRAQ5 (dilution 1:1000, nuclear stain) (Biostatus Limited). Alexa fluor 488 goat 
anti-mouse IgG (H+L) (highly cross adsorbed) and alexa fluor 488 goat anti-rabbit IgG (H+L) 
(highly cross adsorbed) (Molecular Probes) served as secondary antibodies for primary 
antibodies against PECAM-1 and E-selectin for samples at 750 RPM, respectively. 
The MHF bundle section designated for flow cytometric evaluation of p-selectin 
expression by adherent ECs was rinsed with 10 U/mL heparin/saline, rinsed in PBS, and treated 
with HEPES buffered saline solution, trypsin/EDTA and trypsin neutralizing solution to remove 
BAECs from the MHFs (Cambrex, CC-5034). BAECs were centrifuged at 220 x g for 5 minutes 
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and resuspended in PBS with calcium and magnesium to make two 0.5 mL samples. One sample 
was incubated in the dark for 20 minutes with 5 μL of 0.1mg/100µL of a monoclonal antibody 
against human p-selectin, as described in section 4.2.2, and flow cytometry was performed on all 
samples. 
5.2.4 Statistics 
Results are displayed as ± standard error of the mean (SE). One-way ANOVA testing was used 
to compare BAEC coverage and thrombotic deposition. Bonferroni and Tukey’s multiple 
comparison tests were used to compare surface modification data at each time point, and 
comparison of time points for specific surface modifications (p < 0.05). A Student’s t-test was 
used to compare p-selectin expression between different rotations for MHF bundles. 
 
5.3 RESULTS 
5.3.1 Bovine blood collection and preparation 
Heparin levels of 0.6 U/mL were commonly chosen for experiments involving MHF patches and 
bovine blood exposure. Heparin levels of 0.8 U/mL heparin were selected for experiments that 
exposed rotating MHF bundles to bovine blood. This was based on thrombotic deposition 
obtained on control, unmodified PMP MHF patches incubated in varying heparin concentrations 
and rotated for 2 hours on a hematology mixer. Higher levels of thrombotic deposition, therefore 
lower levels of heparinization, were desirable for experiments involving thrombotic on surface 
modified, endothelialized MHF patches, since thrombotic deposition was being evaluated via 
light microscopy only. Lower levels of thrombotic deposition, therefore higher levels of 
heparinization, were desirable on endothelialized MHF bundles, since SEM and confocal 
imaging were used to evaluate thrombotic deposition and EC phenotype, respectively. Enough 
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thrombotic deposition to compare MHF bundles with and without endothelialization was desired, 
however, it was valuable to view the underlying EC. 
5.3.2 MHF patches exposed to bovine blood 
Both percent of EC coverage and type of surface modification greatly influenced thrombotic 
deposition on MHF patches. Thrombotic deposition was compared via light microscopy on a 
non-endothelialized, non-modified MHF patch compared to an endothelialized MHF patch 
surface modified with RFGD and fibronectin adsorption (Figure 5-1).  
a) 
b) 
~ 2 cm 
 
Figure 5-1 Thrombotic deposition shown on MHF patches with light microscopy 
Thrombotic deposition is shown with light microscopy a) non-modified, endothelialized MHF patch, b) 
endothelialized MHF patch surface modified with RFGD treatment and fibronectin adsorption 
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Thrombotic deposition can be compared in electron micrographs on an endothelialized, non-
modified MHF patch relative to an endothelialized MHF patch modified with RFGD and 
fibronectin adsorption (Figure 5-2). Figure 5-2a shows thrombotic deposition in the lower left 
hand corner, including platelets and erythrocytes. Figure 5-2b shows confluent EC coverage 
without thrombotic deposition. 
 
a) b) 
Figure 5-2 Thrombotic deposition on MHF patches shown by SEM 
a) non-modified, non-endothelialized, b) endothelialized MHF patch surface modified with RFGD 
treatment and fibronectin adsorption 
 
 In general, higher BAEC coverage resulted in lower thrombotic deposition (Figure 5-3).  
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Figure 5-3 Thrombotic deposition on endothelialized PMP MHF patches 
Varying surface modifications are shown for day 1-7 of BAEC growth. By day 5 of BAEC growth, MHFs 
treated with RFGD and gelatin (indicated by *) or fibronectin (indicated by +) adsorption had significantly 
(p<0.05) less thrombotic deposition than untreated MHFs or MHFs treated with RFGD and collagen 
adsorption. Error bars represent SE. 
 
MHF patches treated with RFGD and collagen adsorption were the exception. By day 7 of 
BAEC growth, a critical point of endothelialization appeared to be achieved which resulted in 
non-significant differences in thrombotic deposition levels between surface types. This critical 
level of endothelialization was different for each surface type. Only MHF patches treated with 
RFGD and gelatin or fibronectin adsorption reached near confluence by day 7 of BAEC growth.  
MHF patches without surface modification had the lowest EC coverage compared to surface 
modified MHF patches at all days. Thrombotic deposition on non-modified patches did not show 
a significant difference from other groups until day 5, when thrombotic deposition on non-
modified patches was shown to be statistically higher than all groups except RFGD with collagen 
(Figure 5-3). Untreated MHFs reached a maximum of 10% (± 1.2% SE) BAEC coverage within 
the 7 day growth period. 
RFGD + Collagen
RFGD + Gelatin
RFGD + Fibronectin
*
+
 71 
MHF patches treated with RFGD alone had significantly less thrombotic deposition than 
MHF patches treated with RFGD and collagen by day 1 (p<0.05). By day 5 thrombotic 
deposition was also significantly less on RFGD modified MHFs than untreated MHFs (p<0.05). 
MHFs treated with RFGD reached a maximum of 27% (± 5.8% SE) BAEC coverage within the 
7 day growth period. 
MHF patches treated with RFGD and collagen adsorption had significantly more thrombotic 
deposition than RFGD or RFGD and fibronectin treated MHF patches by day 1 (p<0.05). By day 
3 of BAEC growth RFGD and collagen treated MHFs had significantly more thrombotic 
deposition than all groups except untreated MHFs, which was observed again on day 5 of BAEC 
growth (p<0.05). A significant difference in thrombotic deposition was not shown between 
untreated and RFGD plus collagen treated MHFs at any of the days. Maximum BAEC coverage 
for RFGD plus collagen treated fibers reached 36% (± 4.6% SEM) within 7 days. 
MHF patches treated with RFGD and gelatin adsorption performed equivalently to RFGD 
and fibronectin treated MHF patches in relation to thrombotic deposition by day 3. Both groups 
had significantly less thrombotic deposition than RFGD and collagen treated MHF patches by 
day 3 of BAEC growth (p<0.05). At day 5 of BAEC growth both groups had significantly less 
thrombotic deposition than untreated and RFGD with collagen treated MHF patches (p<0.05). At 
no time was there a significant difference in thrombotic deposition between MHF patches treated 
with RFGD and gelatin or RFGD and fibronectin (p<0.05). MHF patches treated with RFGD and 
gelatin adsorption had a maximum BAEC coverage of 70% (± 9.8% SE) within the 7 day growth 
period. MHFs treated with RFGD and fibronectin adsorption reached a maximum of 84% (± 
18% SE) BAEC coverage within the 7 day growth period. 
Amongst groups it can be seen in Figure 5-3 on what day of BAEC growth significant 
differences in thrombotic deposition occurred. Untreated MHFs did not show statistically 
significant differences in thrombotic deposition at any day. MHFs treated with RFGD alone only 
showed a significant difference between day 2 and 5 (p<0.05). Thrombotic deposition was not 
different between days 3, 5 and 7. BAEC coverage in the range of 8% (± 1.8% SE) to 27% (± 
5.8% SE) did not result in significantly lower levels of thrombotic deposition for RFGD treated 
fibers. MHFs treated with RFGD and collagen adsorption showed a significant difference only at 
day 7, indicating lower thrombotic deposition than all other days (p<0.05). MHFs treated with 
RFGD and gelatin adsorption showed a significant difference at day 5 compared to day 1 and 2 
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(p<0.05). Significant differences in thrombotic deposition did not occur for fibers with 16% (± 
4.6% SE) to 70% (± 9.8% SE) BAEC coverage for this group. For MHFs modified with RFGD 
and fibronectin adsorption, there was not a significant difference between days 3, 5 or 7. BAEC 
coverage ranged from 22% (± 5.9% SE) to 84% (± 18% SE). 
5.3.3 MHF bundles exposed to bovine blood 
MHF bundles were rotated at 250 RPM (n=4) or 750 RPM (n=3) in bovine blood for 2 hours. 
Electron micrographs show comparable thrombotic deposition between control untreated and 
non-endothelialized MHF bundles and MHF bundles that were endothelialized and surface 
modified at each fiber layer (  and Figure 5-4 Figure 5-5). High levels of thrombotic deposition 
were found on the inner layer of both the control (Figure 5-4 a) and the endothelialized fiber 
(Figure 5-4d). Moderate deposition is shown on the middle and outer fiber layers of control and 
endothelialized bundles (Figure 5-4 b,c,e,f). Moderate to heavy levels of thrombotic deposition 
are shown on the control MHF bundle after rotation at 750 RPM (Figure 5-5 a,b,c). Mild 
deposition is shown on the inner and outer fiber layers of the endothelialized bundle (Figure 5-5 
d,e). Mild to moderate coverage is shown on the middle fiber layer of the endothelialized fiber 
bundle (Figure 5-5f). Electron micrographs shown are representative of multiple images that 
were taken. 
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 a) 
b) 
c) 
d) 
e) 
f) 
Figure 5-4 Electron micrographs of MHF bundles following rotation at 250 RPM and bovine blood 
exposure 
a) inner layer: control without surface modification or endothelialization, b) middle layer: control without 
surface modification or endothelialization, c) outer layer: control without surface modification or 
endothelialization, d) inner layer: surface modified with Radio Frequency Glow Discharge and fibronectin 
adsorption, and endothelialization, e) middle layer: surface modified with Radio Frequency Glow 
Discharge and fibronectin adsorption, and endothelialization, f) outer layer: surface modified with Radio 
Frequency Glow Discharge and fibronectin adsorption, and endothelialization 
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a) 
b) 
c) 
d) 
e) 
f) 
Figure 5-5 Electron micrographs of MHF bundles following rotation at 750 RPM and bovine blood 
exposure 
a) inner layer: control without surface modification or endothelialization, b) middle layer: control without 
surface modification or endothelialization, c) outer layer: control without surface modification or 
endothelialization, d) inner layer: surface modified with Radio Frequency Glow Discharge and fibronectin 
adsorption, and endothelialization, e) middle layer: surface modified with Radio Frequency Glow 
Discharge and fibronectin adsorption, and endothelialization, f) outer layer: surface modified with Radio 
Frequency Glow Discharge and fibronectin adsorption, and endothelialization 
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Figure 5-6P-selectin expression by BAECs as measured by flow cytometry is shown in . 
BAECs from tissue culture flasks were stimulated with TNF-α or IL-1β, to serve as positive 
controls (Figure 5-6). Incubation of cells with the secondary antibody alone is indicated by 2º. 
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Figure 5-6 P-selectin expression for control BAECs from tissue culture flasks 
BAECS were non-stimulated control, stimulated with TNF-α or stimulated with IL-1β. Incubation with the 
secondary antibody alone is indicated by 2º. 
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Average values of p-selectin expression (± SE) by BAECs taken from surface modified MHF 
bundles rotated in bovine blood for 2 hours are shown (Figure 5-7).  
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Figure 5-7 P-selectin expression by BAECs from endothelialized MHF bundles  
MHF bundles were surface modified with RFGD treatment and fibronectin adsorption, following rotation 
 
P-selectin expression on MHF bundles spun at 250 RPM and on MHF bundles spun at 750 RPM, 
were not significantly different, although a trend towards higher expression at lower RPM was 
seen. Low levels of PECAM-1 expression and moderate levels of e-selectin expression were 
observed with confocal imaging. Refer to Appendix E for PECAM-1 images. 
5.4 DISCUSSION 
The focus of this chapter has been to explore the effect that endothelialization has on the blood 
biocompatibility in the biohybrid lung prototype. Data in Figure 5-3 show that both the type of 
surface modification and the amount of EC coverage directly influence thrombotic deposition on 
MHF patches. It was shown that with less than 100% BAEC coverage, equivalent levels of 
thrombotic deposition occurred, ranging from 22-84% BAEC coverage for MHF patches treated 
with RFGD and fibronectin adsorption in this experiment, for example. At low levels of BAEC 
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coverage, roughly 10% or less, thrombotic deposition was relatively high for all surface types. 
This is illustrated in figure 5-3 for days 1 and 2 in particular. Therefore, little difference was seen 
in comparison of thrombotic deposition for low BAEC coverage. MHFs treated with RFGD and 
collagen adsorption were the exception to this, resulting in statistically significantly higher 
thrombotic deposition than some groups, namely RFGD or RFGD with fibronectin adsorption, 
by day 1 (p<0.05). This finding was not unanticipated, considering that collagen is a pro-
thrombotic protein [137]. Similar to the effect seen with low BAEC coverage being associated 
with high thrombotic deposition, by day 7 of BAEC growth EC coverage was high enough on all 
surface types that nearly equivalent levels of low thrombotic deposition were observed. An 
alternative control, such as irradiated ECs or a non-EC cell type, could have also been utilized 
for thrombotic deposition comparisons on MHFs to further address the question of whether or 
not the EC phenotype was responsible for decreased thrombotic deposition. 
Day 5 of BAEC growth showed the most notable results (Figure 5-3). MHFs surface 
modified with RFGD and fibronectin, and MHFs surface modified with RFGD and gelatin had 
significantly less thrombotic deposition than untreated MHFs or MHFs treated with RFGD and 
collagen. Others have noted the importance of proteins such as fibronectin for cell attachment 
and retention [72, 81, 82]. Takagi et al. have also studied development of a hybrid artificial lung 
with endothelialized MHFs. There experiments evaluated EC adherence and serum properties 24 
hrs after seeding and 1 hr of in vivo bypass in a rat model. Rotation of endothelialized MHFs and 
evaluation of thrombotic deposition were not addressed. Instead, key endpoints were change in 
IL-10 (an inflammation inhibitor) and TNF-α (an inflammation inducer) levels in serum. Serum 
exposed to endothelialized bypass circuits resulted in an increase of IL-10 levels and decrease in 
TNF-α levels compared to non-endothelialized circuits. These findings support suppression of 
inflammation with the addition of ECs to MHFs oxygenation systems [72, 138].  
Two major contributors to thrombotic deposition and experimental outcome were the 
level of heparin in the blood and ease of the blood draw. Heparin levels appropriate for 
comparison of surface modified MHF patches were determined by a control experiment utilizing 
non-modified patches exposed to varying heparin concentrations ranging from 0.5-0.8 U/mL. 
Patches that presented very low thrombotic deposition were not desirable since a good 
comparison could not be made between surface modifications. Likewise, complete thrombotic 
deposition occurring early in the incubation process was not desirable.  Factors, such as air in the 
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collection bag and the quality of the blood draw also contributed to the amount of heparin 
needed. Efforts were made to eliminate as much air as possible from the collection system. 
Problems associated with the blood draw were more difficult to control. Younger bovines often 
had smaller jugular veins which frequently caused the needle to slip in and out of the vein with 
swallowing during collection. Some bovines would startle during the draw, causing the needle to 
slip out, requiring several repeat sticks. In general, older bovines had larger veins and were less 
likely to struggle. This resulted in fewer problems with the blood draw, and a need for lower 
anticoagulation. Control experiments were run with each blood collection to provide suitable 
comparisons. 
 The presence of an inflammatory phenotype for ECs was evaluated by increased 
expression of PECAM-1, p-selectin or e-selectin, known indicators of inflammation [77, 79, 
139]. Expression ranged from low to moderate for all MHF bundles tested at 250 RPM and 750 
RPM. Significant differences between levels of p-selectin expression were not found between 
endothelialized MHF bundles rotated at 250 RPM and 750 RPM. EC phenotype was also 
evaluated indirectly in terms of thrombotic deposition that was apparent in electron micrographs. 
Endothelialized MHF bundles surface modified with RFGD and fibronectin adsorption did not 
show an obvious reduction in thrombotic deposition in comparison to untreated MHF bundles 
without endothelialization at 250 RPM. These bundles did show very similar levels of deposition 
in comparison to controls of untreated bundles. At 750 RPM endothelialized MHF bundles 
surface modified with RFGD and fibronectin adsorption did appear to have less thrombotic 
deposition than control MHF bundles. Therefore, speed of rotation could have an impact on 
thrombotic deposition on MHFs coupled to type of surface modification and level of 
endothelialization. These experiments are somewhat limited by the nature of being in vitro, acute 
experiments, however the in vitro results displayed an encouraging trend.  
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6.0  HYPEROXIA IN THE BIOHYBRID LUNG PROTOTYPE 
6.1 INTRODUCTION 
Oxygenation of the biohybrid lung is described in relation to EC phenotype, limitation of oxygen 
transfer in the presence of an EC layer, and the relationship between bundle rotation rate and 
oxygen accumulation in the fluid phase of the device. This chapter seeks to determine if oxygen 
accumulation will be less in cell culture medium or blood for endothelialized MHF bundles 
compared to non-endothelialized MHF bundles in the biohybrid lung prototype. It addresses 
changes in oxygen accumulation associated with rotational speed. And, the EC phenotype is 
evaluated after exposure to hyperoxia at 95% oxygen. 
 As discussed in section 1.5.4, ECs exposed to hyperoxia may upregulate p-selectin, e-
selectin and/or other indicators of an inflammatory phenotype. If an inflammatory phenotype is 
expressed, an increase in thrombotic deposition on endothelialized MHFs would be expected, in 
comparison to endothelialized MHFs exposed to blood under normoxic conditions. It was also 
noted in section 1.4.1.1, that  coating MHFs can result in lower gas transfer in comparison to 
uncoated MHFs.  
6.2 METHODS 
6.2.1 Oxygen accumulation in cell culture medium in the biohybrid lung prototype 
12-24 hrs after the target speed was attained in the biohybrid lung prototype, a stream of 95% O2 
and 5% CO2 was added through the lumen of the fiber bundle for 24 hrs. The gas mixture 
traveled from a gas tank (1.5 psi) through tygon tubing (approximately 15 feet in length) into the 
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gas pathway inlet of the biohybrid lung and exited through the gas pathway outlet. An outlet to 
air was instituted just before the gas inlet site to maintain desired pressure within the biohybrid 
lung prototype. The exiting gas stream was pulled by vacuum and maintained at a flow of 0.05 
lpm (Fathom Technologies, model GR116-1-A-PV). Transducers were used to close the system 
to atmospheric pressure and maintain the desired flow rate. 
 Cell culture medium samples (0.4 mL) were taken from the distal medium port at 1, 3, 5, 
10, 20, 30, 45 and 60 minutes following introduction of 95% O2 and 5% CO2. Samples were 
collected in gas tight glass syringes (Hamilton Company, 81320) and immediately run on an 
ABL 520 or ABL 5 (Radiometer Copenhagen) to obtain pO  and pCO2 2 levels (n=5 for each 
speed).  Non-endothelialized, non-surface modified polymethylpentene (PMP) MHF bundles 
were setup in the biohybrid lung prototype and spun at the target speed of 250 RPM or 750 RPM 
in cell culture medium to serve as controls. pO2 and pCO2 levels were obtained at the same time 
points for controls (n=3 for each speed). If 95% O  and 5% CO2 2 accumulated on the liquid side, 
pO  values of 722 mmHg would be expected, and pCO  values of 38 mmHg would be expected. 2 2
 
6.2.2 Bovine blood collection and preparation 
Blood was collected as described in section 5.3.1. Blood was first heparinized with 1 U/mL, then 
subsequently re-calcified with 1M CaCl2+ to a final concentration of 2-3 mM calcium and 
balanced to a pH of 7.4 with 1M NaOH on an ABL (700 series, Radiometer Copenhagen). All 
blood was used within 24 hours of collection and stored at 2-8°C prior to use. Heparinized blood 
was warmed in an incubator at 37°C for 15 minutes prior to use.  
 
6.2.3 Oxygen accumulation in bovine blood in the biohybrid lung prototype 
The O /CO2 2 gas mixture was briefly turned off as 120 mL of re-calcified, heparinized bovine 
blood (1 U/mL heparin) was introduced into the system. 50 mL of the blood was left in the 
biohybrid lung prototype for 1 hr of incubation. The gas flow was restored at the beginning of 
the incubation period and 0.4 mL samples of blood from the distal medium port were taken at 1, 
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3, 5, 10, 20, 30, 45 and 60 minutes. Samples were run on an ABL 520 or ABL5 (Radiometer 
Copenhagen) to obtain pO  levels (n=3 for each speed).   and pCO2 2
 Non-endothelialized, non-surface modified PMP MHF bundles were setup in the 
biohybrid lung prototype and spun at the target speed of 250 RPM or 750 RPM to serve as 
controls. 120 mL of re-calcified, heparinized bovine blood (1 U/mL heparin) was passed through 
the system, with 50 mL of the blood left in the biohybrid lung prototype for 1 hr of incubation. 
The blood was sampled with the above protocol to collect pO  and pCO2 2 levels (n=3 for each 
speed). 
6.2.4 Evaluation of endothelialized MHF bundles following hyperoxia and bovine blood 
exposure 
Following incubation, the biohybrid lung prototype was disassembled and the MHF bundle was 
removed. Control MHF bundles were cut in half for light microscopy imaging and SEM 
preparation. Endothelialized MHF bundles were cut in quarters for light microscopy imaging, 
SEM imaging, confocal imaging and flow cytometry evaluation. Bundle portions designated for 
light microscopy were rinsed and stored in 10 U/mL heparin/saline rinse solution. Bundle 
portions designated for SEM imaging were rinsed in 10 U/mL heparin rinse solution, rinsed in 
PBS, soaked in 2.5% gluteraldehyde at room temperature for 1 hour, rinsed in PBS 3 times and 
stored in PBS. Bundle portions designated for confocal imaging were rinsed in 10 U/mL heparin 
rinse solution, rinsed in PBS, fixed in 2% paraformaldehyde and rinsed in PBS for two minutes. 
The MHFs were subsequently labeled with antibodies against PECAM-1 (mouse anti-ovine 
CD31, Serotec, MCA1097) or E-selectin (CD62E/Endothelial Leukocyte Adhesion Molecule, 
Labvision, RB-070-P) (dilution of 10 μL antibody to 500 mL PBS) as described in section 5.2.3. 
The bundle section designated for flow cytometry was prepared as described in section 4.2.2 for 
evaluation of p-selectin expression.  
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6.2.5 Statistics 
Results are displayed as ± standard error of the mean (SE). One-way ANOVA testing was used 
to compare pO2 levels. Tukey’s multiple comparison and LSD comparison tests were used to 
compare data from different test conditions (speed of rotation or with or without BAEC) at each 
time point (p < 0.05). The LSD comparison is a simple comparison test based on an overall F-
test, with the disadvantage that it does not adequately control experimentwise error rates. 
Tukey’s multiple comparison test is considered overly conservative in most cases, it is based on 
the studentized range statistic, and controls well for experimentwise error rate [140]. A t-test was 
used to compare p-selectin expression between different rotations for MHF bundles. 
 
6.3 RESULTS 
6.3.1 Oxygen accumulation in cell culture medium in the biohybrid lung prototype 
A plot of oxygen accumulation data in cell culture medium for MHF bundles with or without 
BAECs rotated at 250 RPM and 750 RPM is shown below (Figure 6-1).  
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Figure 6-1 Oxygen accumulation in the biohybrid lung prototype in cell culture medium 
 
Oxygen levels appeared to reach a steady equilibrium state by 20 minutes, therefore data past 20 
minutes are excluded. MHF bundles rotated at 750 RPM have a faster accumulation in oxygen 
than MHF bundles rotated at 250 RPM. However, significant differences between groups at each 
specific time were not found. Non-endothelialized, non-surface modified MHF bundles trended 
toward a faster accumulation in oxygen than surface modified, endothelialized MHF bundles, but 
the data were not significantly different at specific time points.  
If a less stringent test for significance is applied, the LSD comparison test, some 
statistical correlations can be made between groups. At t = 1 minute there is a significant 
difference between non-endothelialized, non-surface modified MHF bundles and endothelialized, 
surface modified MHF bundles at 750 RPM (p<0.05). At t = 20 minutes the same is true for 
MHF bundles rotated at 250 RPM (p<0.05). 
Significant differences in CO2 accumulation in cell culture medium between 
endothelialized and non-endothelialized MHF bundles, or bundles rotated at 250 RPM or 750 
RPM were not found either (Figure 6-2). 
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Figure 6-2 Carbon dioxide accumulation in the biohybrid lung prototype in cell culture medium 
(95% O2 & 5% CO2 mixture, ± SE) 
6.3.2 Oxygen accumulation in bovine blood in the biohybrid lung prototype 
Oxygen accumulation data in blood for MHF bundles with or without BAECs rotated at 250 
RPM and 750 RPM are plotted below (Figure 6-3). 
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Figure 6-3 Oxygen accumulation in the biohybrid lung prototype in blood 
 
As in cell culture medium, MHF bundles rotated at 750 RPM result in higher levels of pO2 for 
each time point than MHF bundles rotated at 250 RPM. Significant differences are seen between 
non-endothelialized, non-surface modified MHF bundles at time points of 1 and 3 minutes 
(p<0.05). At 750 RPM non-endothelialized, non-surface modified MHF bundles have higher pO2 
values than endothelialized, surface modified MHF bundles. A significant difference was 
observed at the first time point, 1 minute (p<0.05). At 250 RPM pO2 values coincide for the first 
3 time points and are not significantly different at the remaining time points.  
 Again, if a less rigorous test of significance is applied, the LSD comparison test, more 
statistical differences can be found between groups. At t = 3, 5 and 10 minutes, there is a 
significant difference between endothelialized, surface modified MHF bundles rotated at 250 
RPM and 750 RPM (p<0.05). At t = 5 minutes there is a statistically significant difference 
between non-endothelialized, non-surface modified MHF bundles rotated at 250 RPM or 750 
RPM (p<0.05). 
No statistically significant differences were found between rotational speed, or 
endothelialized versus non-endothelialized MHF bundles for CO2 accumulation evaluated in cell 
culture medium (Figure 6-4). 
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Figure 6-4 Carbon dioxide accumulation in the biohybrid lung prototype in blood 
(95% O2 & 5% CO2 mixture, ± SE) 
6.3.3 Evaluation of endothelialized MHF bundles following hyperoxia and bovine blood 
exposure 
Electron micrographs of thrombotic deposition on non-endothelialized/non-surface modified 
MHF bundles exposed to hyperoxia (panels a,b,c), endothelialized/surface modified MHF 
bundles (panels d,e,f), and endothelialized/surface modified MHF bundles (panels g,h,i) exposed 
to hyperoxia rotated at 250 RPM or 750 RPM are shown (Figure 6-5 and Figure 6-6, respectively 
to speeds).  On the inner fiber layer (figure 6-5 a,d,g and figure 6-6 a,d,g) thrombotic deposition 
is comparable between the three groups. On the middle fiber layer (Figure 6-5 b,e,h and Figure 
6-6 b,e,h) and outer fiber layer (panel c, f and i) endothelialized MHFs show equivalent or less 
thrombotic deposition than non-endothelialized MHFs. Images are representative of the sample 
population. 
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Figure 6-5 Electron micrographs of MHF modules rotated at 250 RPM exposed to bovine blood and hyperoxia 
Control without surface modification or endothelialization, with 95% O2 & 5% CO2: a) inner fiber layer, b) middle 
fiber layer, c) outer fiber layer 
Surface modified with RFGD treatment and fibronectin adsorption, and endothelialization, without oxygenation:  d) 
inner fiber layer, e) middle fiber layer, f) outer fiber layer 
Surface modified with RFGD treatment and fibronectin adsorption, and endothelialization, with 95% O2 & 5% CO2: 
g) inner fiber layer, h) middle fiber layer, i) outer fiber layer 
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Figure 6-6 Electron micrographs of MHF modules rotated at 750 RPM exposed to bovine blood and hyperoxia 
Control without surface modification or endothelialization, with 95% O2 & 5% CO2: a) inner fiber layer, b) middle 
fiber layer, c) outer fiber layer 
Surface modified with RFGD treatment and fibronectin adsorption, and endothelialization, without oxygenation:  d) 
inner fiber layer, e) middle fiber layer, f) outer fiber layer 
Surface modified with RFGD treatment and fibronectin adsorption, and endothelialization, with 95% O2 & 5% CO2: 
g) inner fiber layer, h) middle fiber layer, i) outer fiber layer 
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 Positive and negative controls for e-selectin expression are shown on endothelialized, 
surface modified MHF patches (Figure 6-7). The positive control was stimulated with IL-1β, an 
inflammatory cytokine, for 5 hours prior to labeling. The nucleus is shown in blue and e-selectin 
is shown in green. 
a)
b)
 
Figure 6-7 Confocal images of positive and negative immunofluorescent controls for e-selectin 
MHF patches surface modified with Radio Frequency Glow Discharge and fibronectin adsorption, and 
endothelialized, E-selectin = green, Rhodamine-Phalloidin = red, DRAQ5 = blue: a) control, b) IL-1β 
stimulation for 5 hrs 
 
Inner, middle and outer fiber layer of an endothelialized, surface-modified MHF bundle exposed 
to hyperoxia (95% O2 & 5% CO ) and bovine blood, rotated at 250 RPM (Figure 6-8).  2
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Figure 6-8 E-selectin expression by ECs on the biohybrid lung prototype MHFs under hyperoxia at 250 RPM 
Confocal images of endothelialized MHF bundles surface modified with RFGD treatment and fibronectin 
adsorption, following rotation at 250 RPM, bovine blood exposure, and 95% O2 & 5% CO2 for 24 hrs E-
selectin = green, Rhodamine-Phalloidin = red, DRAQ5 = blue: a) inner layer, b) middle layer, c) outer layer 
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Inner, middle and outer fiber layer of an endothelialized, surface-modified MHF bundle exposed 
to hyperoxia (95% O2 & 5% CO ) and bovine blood, rotated at 750 RPM are shown (Figure 6-9).  2
 
a) 
b) 
c) 
50 um 
50 um 
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Figure 6-9 E- selectin expression in the biohybrid lung prototype under hyperoxia at 750 RPM 
Confocal images of endothelialized MHF bundles surface modified with RFGD treatment and fibronectin 
adsorption, following rotation at 750 RPM, bovine blood exposure, and 95% O2 & 5% CO2 for 24 hrs E-
selectin = green, Rhodamine-Phalloidin = red, DRAQ5 = blue: a) inner layer, b) middle layer, c) outer layer 
 
It should be noted that blood products (i.e. platelets, leukocytes, and erythrocytes) fluoresce 
green as well. Of particular note is the shape of the green area and location of the blue nucleus to 
identify BAECs expressing e-selectin. Low to moderate levels of e-selectin expression are shown 
on the inner and middle fiber layers at both rotational speeds. Moderate levels of e-selectin 
expression are shown on the outer layer of the MHF bundle rotated at 250 RPM, and high levels 
of e-selectin expression are shown on the outer layer of the MHF bundle rotated at 750 RPM. 
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PECAM-1 expression was not observed or observed at very low levels for MHF bundles rotated 
at both speeds (data not shown). 
 P-selectin expression of BAECs taken from MHFs rotated at 250 RPM or 750 RPM are 
shown below (Figure 6-10). Both groups show very low levels of p-selectin expression, as 
evaluated with flow cytometry. 
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Figure 6-10 P-selectin expression for BAECs from endothelialized MHF bundles 
MHF bundles were surface modified with RFGD treatment and fibronectin adsorption, and rotated in 
bovine blood and 95% O2 + 5% CO2: 250 RPM, 750 RPM (+SE) 
 
6.4 DISCUSSION 
6.4.1 Oxygen accumulation in the biohybrid lung prototype 
It was anticipated that gas transfer might be somewhat diminished by the presence of an EC 
layer, as is the case with coatings such as siloxane [39, 67, 141]. To combat lower oxygen 
delivery rates, sub-confluent endothelialization could be applied, active mixing within the device 
could be increased, more fibers could be added or a combination of these approaches could be 
implemented. However, results of oxygen accumulation in cell culture medium and blood did not 
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show a significant decrease as measured by pO2 levels between MHF bundles with or without 
BAECs. It should be noted that BAECs are quite permeable [3, 142], even though they share a 
similar thickness to synthetic coatings, such as siloxane. BAECs have been measured at 0.2 to 
0.4 μm thick [3]. Siloxane coatings on MHFs are typically 0.2  to 2 μm thick [67]. 
 It was also projected that increased speeds of rotation would result in higher levels of 
pO2, or better oxygen delivery into cell culture medium or blood. In bovine blood this trend was 
apparent, and even statistically significant at initial sampling time points, and may be due to the 
oxygen carrying capacity of blood related to erythrocytes and hemoglobin. Perhaps with a larger 
gap between the low and high speeds studied, the experimental evidence would be stronger. The 
experimental sample size was on the low side (n =3 to n=5) due to the complexity of these 
experiments. Another factor that could increase pO2 levels at higher speed could be alternative 
fiber spacing patterns. In the paracorporeal respiratory assist lung (PRAL) developed by 
Federspiel et al., oxygen supplied to blood increased by nearly half between 250 RPM and 750 
RPM [64].  
 Additional experiments or controls could have been investigated based on the above 
findings. The presence of an EC layer may have more of an affect on CO  removal than O2 2 
accumulation, since CO2 removal is an important factor in oxygenator design and can be limited 
by the presence of coatings on MHFs [39, 143]. Experiments involving higher percentages of 
CO  and lower percentages of O  may have shown significant differences in CO2 2 2 accumulation 
that were not observed in the experiments utilizing 5% CO . CO2 2 levels did reach 38 mmHg (5% 
CO ) in experiments, but O2 2 levels did not reach 722 mmHg (95% O2). Air bubbles were 
sometimes present at the higher speeds of rotation in MHF bundles tested in medium, which may 
have caused some error in these results, however overall data trends do not suggest that this 
effect had a significant impact. Yet, further investigations could be performed to understand why 
oxygen levels did not reach equivalent saturation levels in all experiments. In addition, controls 
of LPS, TNF-α or IL-1β could have been used as positive controls against hyperoxia. Langford et 
al. have shown BAEC disruption in the presence of LPS [144]. Marsden et al. has shown 
increased release of endothelin-1 and other alterations in EC phenotype in the presence of TNF-α 
[145]. 
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6.4.2 Evaluation of endothelialized MHF bundles following hyperoxia and bovine blood 
exposure 
In terms of biocompatibility, electron micrographs of thrombotic deposition showed a beneficial 
effect for endothelialized fibers in the biohybrid lung. At both test speeds, 250 RPM and 750 
RPM, thrombotic deposition on endothelialized MHF bundles was equivalent or less than 
thrombotic deposition on non-endothelialized MHF bundles. Elevated levels of PECAM-1 and p-
selectin expression are referenced indicators of inflammatory phenotype for ECs as well [77, 79]. 
PECAM-1 expression evaluated with confocal imaging remained low (refer to Appendix E). 
Levels of p-selectin expression on BAECs were also very low at both rotational speeds.  
Upregulation of e-selectin has been reported in the presence of hyperoxia and 
inflammation for ECs [139]. Confocal images of MHF bundles rotated at 250 RPM or 750 RPM 
showed low to moderate levels of e-selectin expression on all fiber layers except the outer fiber 
layer at 750 RPM. Combined e-selectin, PECAM-1 and p-selectin data suggest that BAECs 
following 24 hr exposure to hyperoxia at 95% may still posses a non-inflammatory phenotype.  
Additional or alternative methods of evaluation were intended for use in evaluation of the 
BAEC phenotype. This list includes increased flow cytometric expression of the monoclonal 
antibody against bovine ICAM-1 (Biovendor, RE11228C100), increased flow cytometric 
expression of the monoclonal antibody against bovine TF (gift of Dr. Stephen Carson at the 
University of Nebraska Medical Center, Omaha, NE), increased flow cytometric expression of 
monoclonal antibody against human VCAM-1 (Serotec, MC907S) and evaluation of apoptosis 
via annexin-v (Sigma, APOAF) binding. All positive controls were stimulated with TNF-α or IL-
1β for 5 or more hours. Upregulation of ICAM-1 was observed for positive controls of HUVECs 
taken from tissue culture flasks, evaluated with flow cytometry. However, ICAM-1 upregulation 
by BAECs could not be elicited. This was true for a monoclonal antibody against human ICAM-
1 as well as a monoclonal antibody against bovines. The selection of antibodies against bovines 
was quite limited. A monoclonal antibody against bovine TF did not show a response to positive 
controls for BAECs either, as evaluated with flow cytometry. This antibody, however, was from 
the 1980’s and had not been used for several years. Antibodies against E-selectin and VCAM-1 
did not show upregulation for positive controls via flow cytometry. They did show upregulation 
when observed with immunoflourescence microscopy. VCAM-1 showed a strong response to 
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stimulation with IL-1β or TNF-α for BAECs seeded on glass coverslips, but this did not translate 
to observable expression on MHFs viewed with confocal microscopy. Annexin-V could not be 
shown to exhibit increased binding with flow cytometry techniques either. BAECs stimulated 
with staurosporine (Sigma, S5921) showed obvious morphological changes that appeared to be 
apoptosis when viewed under a microscope, but the cells did not fluoresce in response to the 
annexin-v assay. 
There seems to be a difference between hyperoxic affects on ECs in vivo as components 
of the vasculature rather than ex vivo or in vitro isolated EC exposure. In experiments involving 
whole lung exposure to hyperoxia, increased leukocyte and blood cell deposition has been 
reported in mice [110]. As discussed in section 1.5.4, changes in CAMs and cytokine levels were 
detected in mouse lungs subjected to 95% to 100% oxygen. ECs exposed to hyperoxia under 
tissue culture conditions do not show many of these deleterious affects [119, 120]. Lack of cell 
proliferation was the primary observation in hyperoxic in vitro cultures [146]. This may be 
attributed a reduction in plasma membrane fluidity, a mechanism for EC dysfunction [147]. 
BAECs exposed to 24 hrs of hyperoxia in the biohybrid lung did not incur higher levels of 
thrombotic deposition in comparison to control bundles. Less thrombotic deposition was 
observed on endothelialized bundles, which may be the most relevant criteria for evaluation of 
EC phenotype in the biohybrid lung prototype. This observation combined with overall low 
levels of e-selectin and p-selectin expression seem to suggest that BAECs maintained a healthy 
phenotype following multiple days (4-8) of rotation and 24 hrs of exposure to hyperoxia. The 
period of hyperoxia was shorter in the experiments for this study than for those in the cited 
literature, but overall strenuous effects on ECs, involving seeding and conditioning to shear 
stress, were longer.  
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7.0  SUMMARY 
7.1 CONCLUSIONS 
A biohybrid lung prototype was developed to explore a potential treatment option for patients 
suffering from ARDS. The biohybrid lung prototype allows for oxygenation through a rotating, 
endothelialized MHF bundle. MHFs were surface modified with RFGD and fibronectin 
adsorption to support EC attachment and growth for improved blood-surface contact within the 
device. ECs were then conditioned to withstand shear stress in the physiologic range. Near 
confluence was maintained at speeds tested up to 1500 RPM, corresponding to 29.6 dynes/cm2. 
The biohybrid lung prototype provides a useful tool to evaluate shear stress on ECs under 
rotation.  
Bovine blood biocompatibility testing with the refined biohybrid lung prototype and 
MHFs used in the biohybrid lung prototype showed favorable evidence for incorporation of ECs 
into an extracorporeal device for extended respiratory support. Levels of BAEC coverage as low 
as approximately 20% showed a significant decrease in thrombotic deposition for MHFs treated 
with RFGD and fibronectin adsorption or RFGD and gelatin adsorption. It was shown that 
surface modification of MHFs with RFGD and gelatin or fibronectin adsorption greatly increased 
EC adherence and proliferation. The presence of ECs greatly reduced thrombotic deposition 
regardless of full confluence. Within the biohybrid lung, ECs provided equivalent or better 
blood-surface biocompatibility on MHF bundles modified with RFGD and fibronectin adsorption 
in comparison to untreated MHF bundles.  
Oxygen accumulation curves in cell culture medium and in blood did not show a 
significant difference between pO2 levels for endothelialized and non-endothelialized MHF 
bundles. This finding provides encouraging evidence that a biohybrid lung may not be limited in 
its ability to provide adequate oxygenation by the EC layer alone. Surface area requirements may 
 97 
not need to be significantly increased due to the presence of an EC layer. It was also observed 
that a higher speed of rotation trended towards higher pO2 levels than the lower test speed. This 
was statistically significant in blood at early time points. Thrombotic deposition on 
endothelialized MHF bundles exposed to 95% hyperoxia was equivalent or less than thrombotic 
deposition on non-endothelialized MHF bundles under 95% hyperoxia. This data in combination 
with low levels of e-selectin and p-selectin expression from BAECs suggested that the cells 
retained a non-thrombogenic, non-inflammatory phenotype, crucial to improving the 
biocompatibility as desired in this application. 
The biohybrid lung prototype is novel in its aggressive approach toward modification of 
ECMO support. It combines active mixing, polymethylpentene MHFs, MHF modification and 
endothelialization. Other groups are pursuing mass transfer augmentation, use of alternative 
MHFs, addition of MHF coatings and even development of hybrid systems, independently. 
These areas of research are generating encouraging results. The biohybrid lung prototype could 
be altered to incorporate desirable attributes of other artificial lung devices under investigation. 
For example, the PRAL demonstrated increased gas exchange with increased rotation [64]. The 
PAL did not [65]. Design specifications, such as fiber spacing, from the PRAL could be 
incorporated into the biohybrid lung prototype to increase gas transfer. Findings from the hybrid 
lung under development by Takagi et al. support incorporation of ECs into an artificial lung for 
improved biocompatibility [72]. The use of PMP fibers to reduce poor wetting is supported by 
Toomasian et al [70]. An advantage that the biohybrid lung has over the above mentioned 
technologies is its combined approach to reduce fiber wetting, enhance gas exchange and 
improve biocompatibility. This comprehensive program may improve mortality rates associated 
with ARDS much more than approaches that address only one area of device insufficiency.    
 There are some limitations to the practicality of the biohybrid lung prototype that are not 
associated with approaches that exclude living cells. Incorporation of the biohybrid lung 
prototype into the intensive care setting would be a significant task. Integration of cell therapies 
into hospitals and patient care procedures are in their infant stages. Current cell therapies are 
limited to direct injection of cells into host tissue. Most facilities are not equipped to handle cell 
culture and expansion, or maintain in vitro/ex vivo cell sterility. Care givers are not trained to 
work with hybrid devices, and may be unaware of the delicate nature of the cells. For example, if 
cells are not maintained at approximately 37 ± 2ºC in the biohybrid lung prototype, they will die. 
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The extra training, equipment and fragility of the biohybrid lung will result in increased costs 
associated with the therapy. Insurance providers are hesitant to cover costs associated with cell 
therapies, unless they fall under approved procedures, such as autologous bone marrow or cell 
transplants [148]. To date, Medicare coverage for cell therapies is limited to autologous and 
allogeneic transplants only in severe cases, such as leukemia, lymphoma and neuroblastoma, for 
example [148]. Therefore it is critical to involve insurance companies in clinical trials to gain 
approval for future procedure/device reimbursement. Unfortunately, this may allow insurance 
providers to dictate the “appropriate science” related to a specific the cell therapy [148].  
In addition, effective methods for autologous cell harvest and expansion have not been 
developed to render large cell counts. Fortunately, considerable effort is being expended to 
address this limitation by several groups to promote other modalities of cell therapy [149, 150]. 
A positive finding in the research shown within this dissertation is that subconfluent 
endothelialization may still provide statistically significant decreases of thrombotic deposition in 
comparison to non-endothelialized MHF bundles. Hurdles associated with incorporation of cell 
therapies into patient care will eventually be overcome as long as the need for cell therapy and 
regenerative medicine persists. 
7.2 FUTURE WORK 
Critical in vitro observations have been made with the biohybrid lung project, which suggest it 
should be further pursued in an animal model. The biohybrid lung prototype would require 
scaling up before it could be tested in the appropriate animal model, such as the bovine. 
However, it is important to address the limitations associated with the biohybrid lung as much as 
possible during scale up. It is also valuable to include relevant beneficial findings from other 
groups. For example, MHF fiber spacing and other design specifications from the PRAL could 
be incorporated into the scaled up version of the biohybrid lung to augment gas transfer with 
rotation.  
Additional work could be done to improve cooling within the bioreactor. Incorporation of 
fluid purged seals could decrease heat generation associated with high torque requirements 
attributed to high levels of rotation. An alternative grip with lower heat conductivity could be 
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placed on the shaft of the MHF bundle to reduce transfer of heat from the motor through the 
titanium shaft. 
Efforts could be taken to improve overall device biocompatibility. Blood entrance and 
exit ports could be optimized to decrease blood damage during blood perfusion. Balloon seals 
and string could be replaced with potentially less thrombogenic materials to separate the gas and 
liquid pathways within the device. Components such as tubing, the acrylic housing and 
connectors could be heparin coated, as is often done with PVC tubing and components of 
clinically used extracorporeal circuits [59].   
Animal trials could be run in a bovine model to compare the enhanced/redesigned 
biohybrid lung prototype to a commercially available oxygenator, such as the heparin coated 
Maxima Plus oxygenator (Medtronic Inc., Anaheim, CA, USA). In vivo trials could initially be 
performed for 3 days. Based on these findings, trials could be extended to 1 week or multiple 
weeks.  
Cell sources could be investigated, as well. ECs could be derived from an autologous 
bovine source through bone marrow or skeletal tissue muscle biopsies for precursor cells. 
Additional work would need to be done to guarantee sterility throughout the process. These cells 
could be expanded in culture, driven toward the EC phenotype and then seeded onto MHF 
bundles. Work could also be done to decrease EC seeding and growth time using the autologous 
source in the MHF bundle seeding process. 
With an in vivo model more sensitive blood monitoring could be done, such as platelet 
count, IL-10 levels in serum, TNF-α levels, p-selectin expression on platelets (for platelet 
activation), CD63 expression (for platelet activation), platelet and leukocyte aggregate 
quantitation, and other assessments. A better understanding of overall hemostasis related to 
incorporation of the biohybrid lung and potential reductions in heparin therapy could be 
developed with an animal model.  
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APPENDIX A 
NOMENCLATURE 
Abbreviations 
 
ACD  Acid Citrate Dextrose 
AMMO Active Mixing Membrane Oxygenator 
APC  Activated Protein C 
ARDS  Acute Respiratory Distress Syndrome 
AT  Antithrombin 
BAEC  Bovine Aortic Endothelial Cell 
CAL  Chronic Artificial Lung 
CAM  Cellular Adhesion Molecule 
COPD  Chronic Obstructive Pulmonary Disease 
EC  EC 
ECMO  Extracorporeal Membrane Oxygenation 
eNOS  Endothelial Nitric Oxide Synthase 
ETO  Ethylene Oxide 
HUVEC Human Umbilical Vein Endothelial Cell 
ICAM-1 Intracellular Adhesion Molecule-1 
IL-(1,6,8) Interleukin-(1,6,8) 
IMO  Intravenous Membrane Oxygenator 
iNOS  Inducible Nitric Oxide Synthase 
IVOX  Intravenous Oxygenator 
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MHF  Microporous Hollow Fiber 
MTT  Methylthiazolyl Diphenyl-tetrazolium 
NO  Nitric Oxide 
PAI-I  Type I Plasminogen Activator Inhibitor 
PAL  Pumping Artificial Lung 
PECAM-1 Platelet Endothelial Cell Adhesion Molecule-1 
PEEP  Positive End Expiratory Pressure 
PMP  Polymethylpentene 
PRAL  Paracorporeal Respiratory Assist Lung 
RFGD  Radio Frequency Glow Discharge 
RGD  Arg-Gly-Asp 
ROS  Reactive Oxygen Species 
SD  Standard Deviation 
SEM  Scanning Electron Micrograph 
SE  Standard Error of the Mean 
TFPI  Tissue Factor Pathway Inhibitor 
TNF-α  Tumor Necrosis Factor-α 
VCAM-1 Vascular Cell Adhesion Molecule-1 
vWF  von Willebrand Factor 
XPS  X-ray Photoelectron Spectroscopy 
 
 
Symbols 
 
a   width 
b  length 
  oxygen concentration of the reservoir Ci
Co  oxygen concentration in the biohybrid lung prototype 
d  gap width between the inner and outer cylinder of the bioreactor 
   pore diameter dp
D  diffusion coefficient of the diffusing gas 
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Dm   diffusion coefficient of oxygen in water 
    gravity effects gө
h  fiber wall thickness 
Hm  EC thickness 
K  permeance 
Kec   permeance of the EC 
Kec/fiber  coated fiber permeance 
Kfiber   permeance of the fiber 
K   liquid-side permeance l
Km  diffusional resistance of the MHF membrane 
   Knudsen number Kn
L  length of the MHF 
M  molecular weight of the given gas 
Q  flow rate 
R  outer radius of the MHF 
R  gas constant 
  outer radius of the MHF bundle R1
Re   Reynolds number 
  radius of the titanium module Ri
  radius of the inner wall of the bioreactor housing Ro
S  oxygen concentration measured from medium 
Sa  atmospheric partial pressure 
  zero oxygen partial pressure So
ECSA   surface area of an EC 
MHFSA   surface area of a MHF 
T  absolute temperature 
Ta   Taylor number 
speed of the inner cylinder in the bioreactor U1  
vr  velocity in the r-direction 
  velocity in the theta-direction  vө
α  solubility coefficient 
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δ   average boundary layer thickness 
ε  porosity 
ө  theta-direction 
λ   mean free path length of the diffusing species 
μ  dynamic viscosity 
ν  kinematic viscosity 
ρ  density 
τ   pore tortuosity 
Ω  angular velocity 
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APPENDIX B 
CELL COVERAGE CALCULTIONS 
Cell coverage on MHFs was estimated from MTT related absorbency values. First, an average 
absorbency value was calculated from 3 samples of solution read spectrophotometrically. A 
linear trend line was fit to the MTT calibration curve to obtain the slope of the curve. The value 
of cells/mL was then calculated from Equation 17. 
 
Equation 17 Cells/mL calculated from MTT readings 
Cells/mL = (average absorbency)/(slope of the MTT calibration curve) 
 
The calculation for surface area for MHFs is given in Equation 18. R is the outer radius 
of the MHF. L is the length of the MHF.  
 
Equation 18 Surface area of MHFs 
( )fibersRLSAMHF #2π=  
 
The value for cells/cm2 was calculated (Equation 19). 
 
Equation 19 Cells/cm2
Cells/cm2 = (cells/mL)/(SA ) MHF
 
The surface area of an individual EC was calculated (Equation 20). Each EC is assumed 
to be elliptical in shape, where a is width (48 μm) and b is length (31 μm) [151]. 
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Equation 20 EC surface area 
4
abSAEC π=  
 
The % (cell) coverage was estimated using Equation 21. 
 
Equation 21 % Coverage of ECs on MHFs 
% Coverage = 100[(cells/cm2)/(cells/ 1 cm2)] 
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APPENDIX C 
PERFUSION OF THE BIOHYBRID LUNG 
Simple calculations were performed to estimate a suitable flow rate for medium perfusion 
through the biohybrid lung prototype. It was assumed that adequately oxygenated medium 
(saturated) would flow from a reservoir through silicone tubing through the bioreactor and back. 
The goal was to provide adequate oxygenation to BAECs on the MHF bundle in the bioreactor. 
The main determinants for medium flow rate (Q) were number of cells in the bioreactor and the 
amount of oxygen consumption required by these cells. The total number of cells can be 
estimated using Equation 22. 
 
Equation 22 Calculation for number of cells on the MHFs 
EC
MHF
SA
SACells =#  
 
Steinlechner-Maran et al. referenced 40 pmolO /sec/1062 cells as the metabolic rate of 
oxygen consumption [152, 153]. OUR is oxygen consumption rate (Equation 23). Equation 24 
gives the estimated flow rate for adequate oxygenation of ECs. 
 
Equation 23 OUR for ECs in the biohybrid lung prototype 
OUR = (metabolic rate of oxygen consumption)(#Cells) 
 
Equation 24 Flow rate 
( )( )
oi CC
CellsOURQ −=
#  
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Co is the oxygen concentration in the biohybrid lung prototype, which was assumed to be 
zero. C  is the oxygen concentration of the reservoir, and was found experimentally. A pOi 2 probe 
(Unisense) was placed in a reservoir of cell culture medium. Oxygen concentration was 
measured from the medium and expressed in pico amps. This value was fit into Equation 25 (as 
variable S) to calculate oxygen concentration.  
Equation 25 Oxygen concentration using a Unisense pO2 probe 
) C  = α ⋅ (S – S ) / (Si o a – So
 
α is the solubility of oxygen in the liquid, S is the signal recorded, So is zero oxygen 
partial pressure, Sa is atmospheric partial pressure. C  was calculated from Equation 25i  to be 284 
μmolO2/L. A minimum flow rate of 0.18 mL/min was calculated through this exercise for a 
MHF surface area of 250 cm2. 
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APPENDIX D 
TAYLOR VORTICES 
Taylor-Couette flow can occur in a coaxial cylinder setup when the inner cylinder rotates 
at a higher speed than an outer cylinder, which leads to toroidal vortices from hydrodynamic 
instability [129]. Taylor-Couette flow is described by the dimensionless Taylor number (Ta) for 
a rotating cylinder within a stationary cylinder (Equation 26) [128, 129]. 
Equation 26 Dimensionless Taylor number 
1
2Re
R
dTa =  
 
The gap width (d) is the width between the inner and outer cylinders (d = 0.004 m). The 
inner radius (R ) is the outer radius of the MHF bundle (R1 1 = 0.0105 m). The Reynolds number, 
Re, is given in Equation 27. 
 
Equation 27 Reynolds number 
ν
dU 1Re =  
 
) is given below in Equation 28 The speed of the inner cylinder (U1 , and adjusted for time 
(60 seconds). The kinematic viscosity (ν) for blood is 2.83x10-6 m2/s [128, 129]. 
Equation 28 Speed of the inner cylinder in a Taylor-Couette system 
( )( )
60
2 1
1
RRPMU π=  
 
 109 
Table 4). Computed Taylor Numbers for speeds of rotation are given below (
 
Table 4 Taylor number for corresponding RPM in the biohybrid lung prototype 
RPM Velocity (m/s) Reynolds # (for blood) Taylor # 
50 0.05 79 2348
100 0.11 157 9390
150 0.16 236 21128
200 0.22 314 37560
250 0.27 393 58688
300 0.33 471 84511
350 0.38 550 115029
400 0.44 628 150242
450 0.49 707 190149
500 0.55 785 234752
550 0.60 864 284050
600 0.66 942 338043
650 0.71 1021 396732
700 0.77 1099 460115
750 0.82 1178 528193
800 0.88 1256 600966
850 0.93 1335 678434
900 0.99 1413 760598
950 1.04 1492 847456
1000 1.10 1570 939010
1050 1.15 1649 1035258
1100 1.21 1727 1136202
1150 1.26 1806 1241840
1200 1.32 1884 1352174
1250 1.37 1963 1467202
1300 1.43 2041 1586926
1350 1.48 2120 1711345
1400 1.54 2198 1840459
1450 1.59 2277 1974268
1500 1.65 2355 2112771
 
High Taylor numbers may be an indication of turbulent flow. Steady vortices are 
observed at Ta < 800. Wavy vortices are described as 800 < Ta < 2000. Turbulent vortices are in 
the range of 2000 < Ta < 10,000-15,000. Turbulence is Ta > 15,000 [129]. Due to the large gap 
between the MHF bundle and the outer housing of the biohybrid lung prototype, turbulent 
vortices are most likely present at a rotational speed as low as 50 RPM. Therefore, shear stresses 
may be higher than estimated in chapter 3. 
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APPENDIX E 
PECAM-1 EXPRESSION BY BAECS ON MHF BUNDLES 
a) 
50 μm 
 
b) 
50 μm 
 
Figure 7-1 PECAM-1 expression by BAECs on MHF bundless exposed to bovine blood 
Middle fiber layers of MHF bundles rotated at: a) 250 RPM, b) 750 RPM 
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a) 
b) 
50 μm 
50 μm 
Figure 7-2 PECAM-1 expression by BAECs on MHF bundles exposed to bovine blood and hyperoxia 
  Outer fiber layers of MHF bundles rotated at: a) 250 RPM, b) 750 RPM 
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APPENDIX F 
PERMEANCE IN THE BIOHYBRID LUNG PROTOTYPE 
To evaluate oxygen delivery in the biohybrid lung prototype, a permeance test system was 
initially constructed. Results obtained from the system ultimately demonstrated large amounts of 
variance that made it difficult to compare permeance values between fiber types, speeds and 
MHFs with and without endothelialization. This prompted use of the ABL for gas measurements 
instead. However, the system is worth discussing and may have potential future use with an 
alternative device or test parameters.   
The permeance test system was composed of an oxygen probe (Unisense, OX-500 fast, 
Aarhus, Germany), tachometer (built specifically for this setup), transducer box (built 
specifically for this setup), flow meter (Fathom Technologies, model GR116-1-A-PV), 
LabVIEW software (National Instruments, version 6), PC, data acquisition card (National 
Instruments, AT-MIO-16E), connector block (National Instruments, CB-68LP) and vacuum 
pump. A carbon dioxide probe could also be introduced into this system. A schematic of the 
permeance test system is shown in Figure 7-3. 
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Figure 7-3 Permeance test system 
 
, 5% COThe permeance was calculated for oxygen by passing the test gas (95% O2 2) 
through the lumen of the fibers. Once the test gas had built up within the surrounding liquid 
(water, for data shown below), the pO2 probe reached a maximum reading. The inflow of gas 
was then changed from the test gas to a washout gas (95% N , 5% CO2 2), and the decay rate was 
recorded. The washout rate constant (λ) was obtained from plotting a log-linear scale of time 
verses pO2, and fitting an exponential curve to the data set. From this method, λ is found 
independently of the gas flow rate through the MHFs, and λ is proportional to the system 
permeability. 
Permeance was calculated from Equation 29 [154].  
 
Equation 29 Permeance for the test system 
K=(λVα)/A 
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The volume (V) of liquid within the biohybrid lung prototype was known. The oxygen 
solubility coefficient (α) is known for water or blood at a given temperature. And the area (A) 
can be calculated for the MHF bundle (expressed as SA  in Appendix B, Equation 18MHF ). 
Permeance has the units of [ml/cm2/s/cmHg]. 
 
Permeance readings, obtained experimentally, are displayed in Figure 7-4.  
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Figure 7-4 Oxygen permeance of polypropylene and PMP MHFs in water 
pO2 was measured from the liquid side of the MHF bundle (n=4 per fiber type, per speed)  
 
Permeance values were computed for increasing speeds of 250 to 1500 RPM for 
polypropylene (n=4) and PMP fibers (n=4). The data show an overall trend of better permeance 
with increasing RPM. However, the correlation is pretty poor with R2 values of 0.35 and 0.31 for 
polypropylene and PMP fibers, respectively. The data also show higher permeance for 
polypropylene fibers than PMP fibers. This is expected since polypropylene fibers have a porous 
surface and PMP fibers do not. The drop in permeance values for PMP fibers at 750 and 1000 
RPM, as well as the drop in permeance values for polypropylene fibers at 1000 and 1250 RPM 
are difficult to explain. This occurrence could be due to experimental error from the sensitivity of 
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the pO2 probe. It also could be due to air forming around the MHF bundle at these elevated 
speeds, which was observed repeatedly.   
To further understand permeance variations expected to occur within the biohybrid lung 
prototype, equations were developed to describe the potential role of an EC layer. Equation 30 
provides an estimated oxygen permeance through a single EC based on an assumed thickness 
(Hm) of 0.2 μm, diffusion coefficient of oxygen in water (Dm) and solubility coefficient of 
oxygen in water (α). Equation 31 combines the permeance of the fiber (Kfiber) with the estimated 
permeance of the EC (Kec) to give a coated fiber permeance (Kec/fiber). 
 
Equation 30 Permeance for an EC layer 
Kec = (Dm ⋅ α) / Hm
 
Equation 31 Permeance for a coated MHF 
Kec/fiber = [(1/ Kfiber) + (1/ Kec)]-1
 
 The calculated Kec in oxygen is 4.5x10-5 ml/cm2/s/cmHg. Kfiber for a PMP fiber 
(Membrana, Wuppertal, Germany) is 1.08x10-3 ml/cm2/s/cmHg [39]. Therefore the combined 
permeance (using equation 33) is 4.32x10-5 ml/cm2/s/cmHg. This calculation suggests that the 
presence of an EC on a MHF will greatly inhibit permeance. However, the EC is a biological 
entity, and Equation 30 may be a poor model of its permeance. 
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